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As glycans are exposed on the surface of living cells, they are instrumental in biological 
processes such as cell-cell interactions, cell growth and cell differentiation. Multivalent 
carbohydrate-based nanomaterials help clarify these processes by mimicking the biological 
activity of carbohydrates. Moreover, nanomaterials have high potential for the imaging of 
diseases or biological processes, and can be further engineered for controlled and targeted 
drug delivery. 
In the first part of this dissertation, a straightforward and robust room temperature one-pot 
synthesis of ultrasmall gold nanoparticles (2 nm) was developed using thio-glucose as a 
reducing and stabilizing agent (Chapter 2). The resultant monodisperse gold nanoparticles 
showed high stability and could be further functionalized using two different conjugation 
methods. These non-cytotoxic nanoclusters were radiolabeled for biodistribution studies in 
vivo, showing accumulation in almost all organs and clearance after 24 h.  
The developed ultrasmall glycosylated gold nanoparticles were utilized to target the 
protozoan parasites Plasmodium falciparum and Toxoplasma gondii (Chapter 3). These 
parasites contain cysteine-rich domains in their surface proteins and could potentially 
capture gold nanoparticles through the well-known thiol-gold affinity. The gold 
nanoparticles were able to efficiently bind all the blood stages of P. falciparum, and both 
intracellular and extracellular T. gondii. Drug conjugation was performed for further in 
vitro and in vivo inhibition studies.  
Flat discoidal mesoporous silica nanoparticles were synthesized and their biological 
applications were investigated (Chapter 4). These novel materials were internalized by 
HeLa cancer cells and showed increased intracellular drug delivery as compared to 
spherical analogues. Moreover, the introduction of cleavable disulfide moieties within the 
mesoporous silica framework enabled investigation of the impact of increasing cleavable 
bonds on the breakability and efficacy of these materials as nanovectors. 
Multivalent glycosylated nanoparticles were synthesized to image biological processes 





and a radiotracer in order to study the blood brain barrier crossing in vivo. Also, plasmonic 
gold nanoparticles were conjugated with a collection of carbohydrates for carbohydrate-
protein interactions studies between green algae and cyanobacteria.  
In conclusion, the design and engineering of glycosylated nanoparticles allows mimicking 
biological processes, obtaining unknown information through imaging techniques, and 






















Glykane sind auf der Oberfläche von lebenden Zellen zu finden und dadurch maßgeblich 
für biologische Prozesse wie beispielsweise die Interaktion von Zellen, Zellwachstum und 
deren Differenzierung verantwortlich. Multivalente, kohlenhydrat-basierte 
Nanomaterialien ermöglichen Studien für eine bessere Klassifizierung dieser Prozesse, da 
diese die biologischen Aktivitäten von Kohlenhydraten imitieren können. Zusätzlich sind 
Nanomaterialien sehr vielversprechend für die Entwicklung von bildgebenden Verfahren 
für biologische Prozesse und können für gezielten Wirkstofftransport eingesetzt werden.  
Im ersten Teil dieser Dissertation wird eine einfache und robuste Ein-Topf-Synthese von 
ultrakleinen Gold Nanopartikeln (2 nm) unter milden Bedingungen (Raumtemperatur) 
präsentiert, bei welcher Thioglukose sowohl als Reduktionsmittel als auch als Stabilisator 
verwendet wird (Kapitel 2). Die resultierenden monodispersen Gold-Nanopartikel 
zeichnen sich durch eine hohe Stabilität aus und konnten mit zwei verschiedenen 
Konjugationsmethoden modifiziert werden. Die nicht-zytotoxischen Nanokluster wurden 
mit radioaktiven Substanzen markiert und für in vivo Biodistributionsstudien verwendet, 
bei welchen eine Akkumulierung in fast allen Organen gefolgt von deren Ausscheidung 
innerhalb von 24 h beobachtet wurde.  
Die ultrakleinen, glykosylierten Gold Nanopartikel wurden zum Targeting der 
protozoischen Parasiten Plasmodium falciparum und Toxoplasma gondii verwendet 
(Kapitel 3). Diese besitzen cysteinreiche Domänen in ihren Oberflächenproteinen wodurch 
aufgrund der hohen Affinität von Gold und Thiolen eine zielgerichtete Bindung möglich 
ist. Die Gold-Nanopartikel konnten alle Blutstadien von P. falciparum, sowie T. gondii  
(intra- und extrazelluläre) effizient binden. Des Weiteren wurden Wirkstoffkonjugate für 
in vitro und in vivo Inhibitionsstudien hergestellt. 
Flache, scheibenförmige Nanopartikel aus mesoporösem Silica wurden hergestellt und auf 
deren biologische Anwendbarkeit getestet (Kapitel 4). Diese neuartigen Materialen wurden 
von HeLa Krebszellen internalisiert und zeigten einen besseren interzellulären 





innerhalb des mesoporösen Silica-Gerüsts ermöglichte die Untersuchung des Einflusses der 
steigenden Zahl von spaltbaren Bindungen auf die Brüchigkeit dieser Verbindungen und 
deren Einsetzbarkeit als Nanovektoren.  
Die Entwicklung bildgebender Verfahren zum Studium biologischer Prozesse wurde 
anhand multivalenter glykosylierter Nanopartikel durchgeführt (Kapitel 5). Im speziellen 
wurden ultrakleine, fluoreszierende Silikon-Nanopartikel mit Glukose und einem 
Radiotracer funktionalisiert und für in vivo Untersuchungen zur Überwindung der Blut-
Hirn-Schranke verwendet. Des Weiteren wurden plasmonische Gold-Nanopartikel mit 
einer Auswahl an Kohlenhydraten konjugiert, um Kohlenhydrat-Protein-Interaktionen 
zwischen grünen Algen und Cyanobakterien zu visualisieren. 
Zusammenfassend wurde in der vorgelegten Arbeit gezeigt, dass glykosylierte 
Nanopartikel für die Nachahmung von biologischen Prozessen, die Entwicklung von 



















Nanomaterials are materials that have at least one dimension between 1 and 100 nm.1 In 
particular, nanoparticles (NPs) are objects in this size range that behave as a whole unit in 
terms of transport and properties. The size of NPs is comparable to the dimensions of 
biomolecules, such as glycans or proteins (Figure 1.1). Hence, the combination of 
nanomaterials with biomolecules allows for mimicking biological entities and 
understanding biological processes.2  
 
Figure 1.1. Nanoparticles have a size between 1 and 100 nm, which is comparable to the size of biomolecules. 
Due to their size, nanomaterials differ significantly from both bulk materials and their 
atomic components, as they present high surface to volume ratio and quantum-size effects 
in the case of metal nanoparticles.3-4 For spherical NPs, the specific surface area increases 
with decreasing diameter (Figure 1.2).5 Since the specific surface area (the surface area of 
a material per unit of mass) increases, the number of atoms at the surface increases 
drastically as well, where for example in a 2-nm NPs, 70% of the atoms are located on the 
surface. For this reason, ultrasmall NPs (size range from 1 to 3 nm) have completely 
different physicochemical and pharmacokinetic features compared to larger nanoparticles 
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as the size becomes comparable to single molecules.5-6 In addition to size, other properties 
like surface charge, material composition and shape have a strong influence in the 
pharmacokinetic properties and in renal clearance of ultrasmall NPs.7  
 
Figure 1.2. The specific surface area as well as the surface atoms of nanoparticles increases with decreasing diameter. 
Reprinted from Zarschler et al.5 Copyright (2016), with permission from Elsevier. 
1.1.1. Types of nanoparticles 
Many different materials have been used to synthesize NPs for biomedical applications, 
such as metals (gold,8 silver9), silica10 and silicon11, carbon (carbon nanotubes,12 
fullerenes,13 graphene14), polymers15 dendrimers,16 magnetic,17 or semiconductive 
materials18. 
1.1.1.1. Metal nanoparticles 
Metal NPs, especially those based on gold, have very special photophysical properties due 
to the quantum-size effect, and are hence exploited in biotechnology applications. The 
quantum-size effect takes place in metal NPs when the de Broglie wavelength of the 
valence electrons is of the same order as the NP size. In this case, the NPs follow the rules 
of quantum mechanics as they behave as zero-dimensional quantum boxes.19 When an 
electromagnetic field interacts with free conduction electrons of the NPs, the electrons start 
to oscillate in phase with the electromagnetic field inducing a dipole within the NP. To 
Chapter 1. Introduction  
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compensate this dipole formation, a restoring force in the NP results in a resonance 
frequency, the so called surface plasmon resonance (Figure 1.3).20 This oscillation depends 
on the NP size, shape, surface ligand and charge, as well as the temperature and the 
surrounding medium, and it is also very sensitive to the proximity of other NPs. The surface 
plasmon band is very characteristic for gold, silver and copper NPs. However, it is absent 
in both ultrasmall NPs (d < 2 nm) and bulk material. 
 
Figure 1.3. Schematic representation of the interaction of an electromagnetic field with a metal nanoparticle that produces 
the oscillation of conduction electrons inducing a dipole within the nanoparticle. 
Gold nanoparticles (AuNPs) have been widely used for biomedical applications due to their 
size and shape, optoelectronic properties, biocompatibility, low cytotoxicity as well as easy 
functionalization.21 As the surface plasmon resonance depends on the proximity among the 
NPs, particle aggregation results in a broadening and a shift to red frequencies of the 
plasmon band that can be visible through a change in color (from red to blue). This property 
has been exploited for biosensing applications, monitoring the interaction of a ligand 
present on the AuNP surface with a specific receptor that produces AuNPs aggregation 
(Figure 1.4).22 This aggregation can be monitored with a UV/Vis spectroscopy or even by 
the naked eye, allowing NPs to be used in biodiagnostic assays. Such biosensors have 
already been used in pregnancy tests, (First Response®) in the 1990s.23 The use of AuNPs 
allows for a better understanding of the binding specificities between different 
biomolecules using a rapid and high-throughput method based on the measurement of 




Figure 1.4. a) Schematic representation of the aggregation of gold nanoparticles upon biomolecular addition. b) UV/Vis 
absorbance spectrum of well-dispersed gold (red) and aggregated (blue) nanoparticles. Reprinted with permission from 
Delbianco et al.22  
Many methods have been established to control the size,25-27 shape28 and surface 
functionalization19 of AuNPs. A perfect control on both size and shape is highly important 
in biomedical applications as it determines the wavelength where the plasmon band has its 
maximum. An emerging application of AuNPs in nanomedicine is photothermal therapy as 
it enables to selectively perform hyperthermia in tumors and avoid damaging healthy 
tissue.29 This process takes place when plasmonic NPs accumulate in tumors and are further 
irradiated with a laser source that has a wavelength in the maximum of the NP surface 
plasmon resonance. The absorbed light is converted into heat that produces irreversible 
damage to the tumor tissue. Since the size and shape of AuNPs is controllable, the surface 
plasmon resonance is usually tuned to the near-infrared (NIR) window to ensure that 
minimum light is absorbed by hemoglobin and water allowing for a deeper tissue 
penetration.30 The typical AuNPs used for hyperthermia applications are nanoshells,31 
nanorods,32 nanocages33 and nanostars,34 as the geometry allows for obtaining small AuNPs 
with a plasmon resonance band in the NIR window. 
The functionalization of AuNPs with biomolecules can be complicated due to the 
complexity of these structures. Surface functionalization of AuNPs usually occurs through 
ligand exchange reactions where thiol functionalized moieties are used to displace adsorbed 
ligands. In this way, the loading efficiency can be controlled by the amount of thiols added, 
and the introduction of two or more thiol ligands allows for multiple conjugation.35 
Functionalization can be done through covalent or non-covalent conjugations.21 Covalent 
conjugations can be achieved through a direct thiol displacement on the gold surface if the 
selected biomolecule has an available thiol moiety.36 If the thiol group is not present, 
covalent bond formation can be performed on AuNPs through coupling reactions37 or click 
Chapter 1. Introduction  
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reactions.38 The covalent bond provides a stable structure permitting the use of NPs for 
applications such as imaging. After a first covalent conjugation, a non-covalent conjugation 
can be further exploited for biofunctionalization through weak interactions such as 
hydrogen bonding,39 electrostatic interactions40 and hydrophobic interactions.41 These 
conjugations are mostly used in drug delivery to facilitate the release of cargo. 
1.1.1.2. Silica and silicon nanoparticles 
Silica NPs, made of silicon dioxide, are a powerful tool for biological applications due to 
their easy synthesis and functionalization, biocompatibility and low cytotoxicity.42-43 Many 
methods have been used to control the size, shape and pore size of silica NPs. In 1968, 
Stöber reported a pioneering method to prepare monodisperse silica nanoparticles of 
controlled size.44 This synthesis uses silicates in a mixture of water, alcohol and ammonia 
to produce different sized NPs, depending on the precursor concentrations. This method 
was further modified to synthesize mesoporous silica nanoparticles (MSNs), silica NPs that 
contain pores with diameters between 2 and 50 nm, by introducing polymer templates 
(often surfactants) that interfere in silica precursor growth. The variation of this polymer 
template as well as the concentration used, allows for control over pore size, structure and 
particle cristalinity.42 Hollow silica nanoparticles have been produced by utilizing a 
polymer template (such as polystyrene particles) coated with polyelectrolytes, through the 
layer by layer assembly technique, to facilitate silica adsorption. The removal of the 
polystyrene template through calcination permits the formation of hollow silica particles.45  
Surface functionalization of silica NPs can be performed using two strategies: through a 
co-condensation strategy during the synthesis of the NPs that is preferable for internal 
functionalization of the mesopores; or through a surface modification after the synthesis. 
The surface functionalization can be achieved by condensation of the available hydroxyl 
groups with halosilanes to incorporate functional groups such as amines or thiols that can 
be further reacted with the desired compounds.42, 46  
Silica NPs have been widely used for drug delivery and imaging. In particular, MSNs have 
been used as nanocarriers because of the high drug loading capacities and the controlled 
drug release through the mesoporous structure. This structure can be modified to host the 
selected molecules that are further released under physiological conditions. The in vivo 
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phamacokinetics can also be controlled by synthesizing monodisperse samples as well as 
tuning the size and structure.47 MSNs have also been widely used for imaging applications 
as it was shown that they are optically transparent allowing for the use of tracers without 
interferences.43, 48 Contrast agents such as metal49 and magnetic NPs,50 organic dyes51 or 
quantum dots52 were encapsulated in MSNs. 
Silicon NPs have recently attracted attention in biomedical applications as they exhibit size 
depending optical properties, easy surface conjugation and low toxicity.53 The 
optoelectronic properties of silicon NPs arise when the particle size is between 1 and 5 nm, 
and hence, these NPs are usually used in the ultrasmall range.54-55 In vivo studies revealed 
that silicon NPs are faster biodegraded when compared to other optically active materials.11 
1.1.1.3. Carbon-based nanomaterials 
Graphite consists of stacked layers of hexagonal sp2-carbon and is the starting material for 
the synthesis of carbon-based nanomaterials. These nanomaterials have unique physical 
properties such as high electrical and thermal conductivity as well as mechanical strength.56 
The most common carbon based materials are carbon nanotubes, fullerenes and graphene 
(Figure 1.5). 
 
Figure 1.5. Structure of different carbon based nanomaterials. 
Carbon nanotubes are composed of a rolled up graphene sheet that forms a seamless 
cylinder. They can be single-walled if they have only one layer or multi-walled if they are 
formed by multiple concentric layers of graphite.57 Carbon nanotubes have metallic, 
semiconducting and superconducting electron transport properties. They have been 
therefore used in many biomedical studies such as diagnostic tools, biosensors and even as 
Chapter 1. Introduction  
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drug delivery devices and for tissue engineering.58 Nevertheless, carbon nanotubes are not 
soluble in most solvents and therefore need to be functionalized to be used in biological 
media.12 Carbon nanotubes can be conjugated to drugs, carbohydrates, peptides or nucleic 
acids for intracellular delivery.59  
Fullerenes are carbon cage molecules in the shape of a soccer ball composed of 60 carbon 
atoms distributed in twelve pentagons and 20 hexagons. Both inner and outer surfaces are 
covered with a sea of electrons.60 The poor solubility in aqueous solutions can be overcome 
by chemical and supramolecular functionalization to increase the solubility in polar 
solvents.61 Similarly to carbon nanotubes, drugs, carbohydrates, peptides and nucleic acids 
can be conjugated to fullerenes for delivery purposes.62    
Graphene is a honeycomb-like monolayer of carbon atoms and is the basic building block 
for other carbon based materials such as carbon nanotubes. Since its discovery in 2004, 
graphene has raised interest in the biomedical field due to its physical, chemical and 
mechanical properties.14, 63 Its flat morphology and excellent mechanical properties render 
graphene not only highly useful for delivery applications and photothermal therapy,64 but 
also for tissue engineering.65   
1.1.1.4. Polymers and dendrimers 
Polymeric NPs are used for biomedical applications due to the versatility of the structures 
used to build the scaffolds that can host and deliver a cargo to a targeting point in response 
to external stimuli or under certain physiological conditions.15 The responsiveness of 
polymeric NPs can be controlled by introducing different functionalities in the scaffold that 
react under change of pH, reducing or oxidizing conditions or upon enzymes.15, 66 
Dendrimers are highly branched three-dimensional polymeric molecules composed by 
identical fragments, dendrons, that originate from a core.67 The stepwise synthetic growth 
allows for obtaining extremely monodisperse samples in contrast to conventional polymers 
where a mixture of particles is obtained. Completely control on the structure and 
composition can be achieved, permitting to exactly modify the physical and chemical 
properties of dendrimers.16 Dendrimers can be conjugated with different functionalities 
depending on the biomedical application, using many different strategies. 
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1.1.1.5. Magnetic nanoparticles 
The most commonly used magnetic NPs for biomedical applications are the biocompatible 
and biodegradable ferrite colloids magnetite (Fe3O4) and maghemite (γ-Fe2O3).17, 68 When 
these NPs are small enough (typically 3-50 nm), each NP is composed of a single magnetic 
domain and behaves like a giant paramagnetic atom with a very fast response to applied 
magnetic fields.69 These superparamagnetic NPs can be used for MRI contrast 
enhancement, tissue engineering, drug delivery, hyperthermia and cell separation, and are 
specially interesting since they do not retain magnetism even after removal of the magnetic 
field.70 
There are several strategies to synthesize iron oxide NPs: physical methods that include 
gas-phase deposition and electron beam lithography; microbial methods and wet chemical 
methods such as sol-gel and oxidation syntheses, co-precipitation, hydrothermal reactions, 
etc.17 After the synthesis, the magnetic NPs need to be functionalized to prevent 
aggregation, as in magnetic suspensions also the magnetic dipolar forces between particles 
may lead to particle aggregation. The stabilization can be achieved by introducing 
functionalities that give electrostatic and steric repulsions between NPs.68  
Covalent bioconjugation of NPs can be done with amines, carboxyls, aldehydes and thiols 
exposed on the nanoparticle surface.68 Magnetic NPs for drug delivery can be designed by 
loading the drug on the NP surface or by introducing a shell that increases the loading 
capabilities.17 Magnetic NPs can also be used in hyperthermia applications by injection into 
a tissue and applying an alternating magnetic field that generates heat due to the magnetic 
hysteresis loss. Similarly to photothermal therapy using plasmonic NPs, magnetic NPs can 
destroy tumors without damaging healthy tissue.17 
1.1.1.6. Quantum dots 
Quantum dots are luminescent semiconductor nanoparticles made of binary compounds 
such as selenides or sulfides of metals such as cadmium or zinc.22 The optical properties 
depend on the quantum dot size and can be tuned.18 Moreover, quantum dots have a broader 
excitation band and sharp emission bands, allowing for multicomponent analysis using a 
single excitation wavelength (Figure 1.6).22, 71 Quantum dots are usually synthesized at high 
temperature in the presence of thiol derivatives such as ZnS or CdS to improve the 
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fluorescent quantum yield, as well as to protect them from photo-oxidation and to minimize 
cytotoxicity.72  
 
Figure 1.6. Absorbance and emission profiles of quantum dots with different sizes. Reprinted with permission from 
Delbianco et al.22  
Before their use in biological systems, quantum dots need to be coated to improve the 
stability, make them water soluble and maintain the fluorescence. So far, quantum dots 
have been used for imaging applications, such as in contrast agents, due to their promising 
optical properties that can be tuned to the NIR window. Nevertheless, some limitations such 
as high toxicity, make them a good complement to existing organic fluorophores rather 
than a replacement.18 
1.1.2. Nanoparticle characterization 
1.1.2.1. Nanoparticle size, shape and surface charge 
The size of nanoparticles is extremely important as it determines the biodistribution and 
retention of the NPs in tissues.73 Dynamic light scattering (DLS) measures the Brownian 
motion of NPs in suspension, which is the random motion of particles in a fluid due to their 
collision with fluid molecules. The Brownian motion can be related to the hydrodynamic 
radius (d (H)) through the Stokes-Einstein equation (1), where the velocity of the Brownian 
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motion is defined by the translational diffusion coefficient (D), k is the Boltzmann’s 
constant, T is the absolute temperature and η is the viscosity. 
𝑑(𝐻) = 𝑘𝑇3𝜋𝜂𝐷						(1) 
DLS measures the mean particle size and homogeneity of size distribution, expressed with 
the polydisperse index (PDI). The main limitation of DLS is the measurement of samples 
containing several size distributions, as the signal of smaller particles is lost because the 
signal intensity of a particle with radius r is proportional to r6, and therefore will be masked 
by larger particles (Figure 1.7).73 
 
Figure 1.7. Dynamic light scattering measurements when the sample contains a) small particles, b) big particles, and c) 
small and big particles.  
Small-angle X-ray scattering (SAXS) measures the variation of the electron density in a 
sample. SAXS can give information about the NP size distribution, shape and surface 
structure such as pore size.74 The interaction of the X-ray radiation with a material causes 
a small deviation of the incident direction, known as small-angle scattering.75 Depending 
on these angular ranges, SAXS can give size information between 1 and 100 nm. 
Nevertheless, this technique, as well as DLS, should be combined with supporting 
techniques such as electron microscopy to get information of both size and shape of NPs. 
Electron microscopy (EM) uses a beam of accelerated electrons and electromagnetic lenses 
to generate images. These images have higher resolution than those obtained with optical 
microscopy due to the shorter wavelength of electrons compared to photons.76  
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Scanning electron microscopy (SEM) uses incident electrons that interact with the sample 
to gain information about the surface topography and composition. Due to the interaction 
of these electrons with the sample, several electrons are emitted, such as secondary 
electrons that are inelastic scattering electrons. The detection of these secondary electrons, 
emitted from the sample surface, is the most common mode in SEM and allows for surface 
imaging with a resolution smaller than 1 nm.76 A limitation of SEM and all EM techniques 
is the destructive sample preparation that also needs to be stable in high vacuum. Moreover, 
to detect the surface electrons, the surface of the sample needs to be electrically conductive 
and therefore might need to be coated with an ultrathin layer of a conducting material, 
usually gold, through low vacuum sputter or high vacuum evaporation. A method to 
overcome the problems of high vacuum during sample preparation and measurements is 
the use of environmental SEM (ESEM) that allows for imaging of wet, uncoated samples. 
This technique permits to image in their natural state without further modifications.77 
In transmission electron microscopy (TEM), the incident electrons are transmitted through 
the sample. As the incident electrons interact with the ultrathin specimen, they are 
transformed into unscattered electrons, elastically scattered electrons or inelastically 
scattered electrons. The scattered and unscattered electrons are focused by electromagnetic 
lenses and projected on a screen to generate an electron diffraction, an amplitude-contrast 
image, a phase-contrast image or a shadow image of varying darkness depending on the 
density of unscattered electrons.78 TEM provides better spatial resolution compared to SEM 
and has the possibility to couple analytical techniques to obtain a better analysis.79 Scanning 
TEM (STEM) allows for imaging of samples completely submerged in a liquid permitting 
observation with high contrast without the addition of contrast agents.80 Another method to 
study biological samples without destroying the native environment is using cryo-electron 
microscopy (cryo-EM), which uses cryogenic temperatures. Cryo-EM allows for imaging 
of biological samples without dehydration or fixation.81 Moreover, the collection of 
multiple images in cryo-EM at different angles permits the formation of 3D images. 
The surface charge of a NP can be measured using the zeta (ζ) potential which determines 
the stability of the NP suspension. Strongly charged NPs (above 30 mV or below -30 mV) 
are more stable thanks to electrostatic repulsions. ζ potential is the electric potential at the 
slipping plane between the dispersed medium and the layer attached to the NP and can be 
determined by measuring the electrophoretic mobility.73 The ζ potential of a sample 
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depends on many parameters such as ionic strength, pH and composition of the dispersed 
medium. Similar to DLS, the main limitation of ζ potential measurements is that the results 
of larger NPs will mask the value of smaller particles.73 
1.1.2.2. Nanoparticle surface chemistry  
Surface modification of NPs influences their biological roles and is able to lower 
cytotoxicity.82 The stabilizers on the NP surface are usually small molecules present in very 
small amounts making the identification and quantification very challenging.83   
NMR spectroscopy for surface characterization is often limited by the low solubility of the 
stabilizers that difficult the small molecules to tumble rapidly to provide a sharp signal.84-
85 Conjugating long and flexible linkers to the NPs increases the solubility which provides 
better NMR spectra.83 Therefore, NMR is a suitable technique to monitor reactions and 
product formation but has limitations for structure elucidation of NP stabilizers.86 
Fourier transform infrared (FTIR) spectroscopy has been widely used to identify functional 
groups present on the surface of NPs. This technique permits to identify specific functional 
groups, such as esters, carbamates, amides or azides.83   
X-ray photoelectron spectroscopy (XPS) is a surface spectroscopic technique that gives 
information about the elemental composition, empirical formula, chemical and electronic 
state of the elements existing within the surface of a material.83 The samples are irradiated 
with an X-ray beam allowing for the escape of surface electrons with a certain kinetic 
energy. This kinetic energy can be related to the binding energy of the emitted electrons 
that depends on the element, the orbital and chemical environment of the atom from which 
the electron is ejected.87  
1.1.2.3. Nanoparticle activity assessment in cells 
To assess the biological behavior of NPs in cells, confocal laser scanning microscopy 
(CLSM) and fluorescence-activated cell sorting (FACS) are powerful tools when the NPs 
are tagged with a fluorescent marker.73  
FACS allows for rapid analysis of multiple characteristics of cells, such as cellular size and 
internal complexity, as well as uptake studies of fluorescent tagged biomolecules or 
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nanoparticles.88 The cells are individually scanned by a laser and the scattered light at 
different angles gives information about the cellular physical properties, whereas the 
emitted light is used to identify fluorescent labelled antibodies and NPs.88 Quantitative 
information is obtained by the determination of the cell population (that permits to 
distinguish between alive and dead cells) and the amount of fluorescent labelled NPs or 
drug internalized by the cells.73  
CLSM is used for imaging of fluorescent tagged biological systems. In combination with 
FACS, confocal microscopy is able to pinpoint the location of the tagged nanomaterial 
within the cells, by using fluorescent tagged antibodies that stain the different organelles. 
With co-localization calculations, the quantification of internalized NPs is possible. 
1.2. Multivalency 
Multivalency involves multiple simultaneous binding between two units, such as a ligand 
and a receptor, and plays a key role in biological processes to establish strong or reversible 
chemical interactions.89 These additive interactions take place between cells or other 
organisms, such as viruses and bacteria and are important in biomedicine.90 
Carbohydrates, together with nucleic acids and proteins, are the most abundant class of 
biopolymers and are mainly used for energy production and as structural materials. Glycans 
are found on the surface of living cells forming a thick layer called glycocalyx (Figure 1.8), 
and are involved in important biological processes such as cell-cell interactions, and they 
regulate important biological functions such as inflammation, cell growth, differentiation 
and adhesion.91 The structural complexity of the glycocalyx makes glycobiology highly 
challenging.92 
 
Figure 1.8. Transmission electron micrographs of the glycocalyx (GCX) on cultured bovine aortic endothelial cells (EC). 
Scale bar = 2 µm. Adapted from Ebong et al.93 Copyright (2011), with permission from Wolters Kluwer Health. 
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Carbohydrates can form hydrogen bonds with other carbohydrates (carbohydrate-
carbohydrate interactions, CCIs) or with proteins (carbohydrate-protein interactions, 
CPIs).91 These interactions are typically very weak (in the mM range), but multivalency 
compensates the low affinity of one binding event. Systems that display multiple identical 
carbohydrates exhibit generally stronger binding affinities than the sum of each single 
contribution.94  
There are different possibilities to construct multivalent networks, such as chelating, 
statistical multivalency, adhesion or sub-site binding (Figure 1.9).95 The binding affinity of 
CPIs is known to depend on size, spatial assembly and valency.94  
 
Figure 1.9. Different possibilities of multivalent binding modes between carbohydrates and carbohydrate receptors.  
1.2.1. Multivalent carbohydrate based nanomaterials 
This section has been modified in part from the following article: 
Carbohydrates in supramolecular chemistry. M. Delbianco, P. Bharate, S. Varela-
Aramburu, P. H. Seeberger, Chem. Rev. 2016, 116, 1693–1752.22 
doi:10.1021/acs.chemrev.5b00516. Copyright 2016 American Chemical Society 
In order to mimic the biological processes that occur in nature, synthetic chemists have 
tried to construct multivalent carbohydrate based scaffolds.96-97 Multivalency has been 
exploited for the design of high affinity ligands that can be used as drugs and probes. 
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Intense efforts have been devoted to better understand this phenomenon as a first step 
toward predicting the optimal density of ligand display.98 
The scaffold at the center of the glycoconjugate serves to classify the systems. Organic 
macrocycles,96, 99-100 dendrimers,101 nanoparticles,102 and polymeric backbones103 are used 
to delineate the classes of carbohydrate-based supramolecular assemblies (Figure 1.10). 
Carbohydrates are used as building blocks for the synthesis and stabilization of 
supramolecular systems based on multiple weak interactions. 
Many supramolecular systems based on nanomaterials have been described.22 
Glyconanomaterials are a suitable platform to detect lectins or study CCIs and CPIs, and 





Figure 1.10. Overview of different glycosylated scaffolds used for supramolecular assemblies. Adapted from Delbianco 
et al.22  
1.3. Nanomedicine 
The use of NPs for biomedical applications such as imaging and therapy of diseases has 
increased in the past decade.104 Scientists have tried to develop multimodal NPs that are 
able to simultaneously accomplish multiple tasks such as imaging and drug delivery, or 
even perform complex functions that require more than one functional unit (Figure 1.11). 
The perfect control of all the important parameters such as surface chemistry, cargo, size, 
shape and matrix is still very challenging.105 Nevertheless, the need of personalized disease 
treatments is pushing the field of nanomedicine forward, with the development of 
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theranostic NPs that can perform diagnosis, imaging, targeted delivery and controlled drug 
release.104 
 
Figure 1.11. Example of an engineered nanoparticle for multimodal drug delivery. 
It is known that NPs without targeting moieties accumulate in tumors more than in normal 
tissues due to the enhanced permeability and retention (EPR) effect of the tumor 
vasculature. NP accumulation in tumors can be explained by the permeability of tumor 
blood vessels together with the ineffective drainage of the lymphatic system.106 Therefore, 
the use of NPs conjugated with cellular targeting carbohydrates increases the 
chemotherapeutic effect for different types of cancers.107 
1.3.1. Imaging 
Fluorescence techniques have been widely used for imaging to identify and track molecular 
recognition events. The most common fluorescent dyes are organic dyes,  comprising a 
wide range of structures with different functionalities, solubility and spectral properties.108 
The main limitation of organic dyes is photobleaching (decrease in fluorescence 
intensity).109 This can be prevent encapsulating the organic dyes to protect them from 
environmental oxygen that affects the photostability.110 Silica NPs are very often used for 
imaging since the synthesis and chemical functionalization is simple and well-stablished. 
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Similar to organic dyes, quantum dots exhibit tunable optical properties for imaging 
applications. The high toxicity of quantum dots is their disadvantage.108  
Magnetic resonance imaging (MRI) is an imaging technique that requires the use of a 
contrast agent such as magnetic nanoparticles and allows for the visualization of the internal 
structure of living organisms. MRI has been used for both in vitro and in vivo imaging and 
is a safer technique than X-ray computed tomography (CT) and positron emission 
tomography (PET).108 PET is a nuclear medicine technique that provides 3D images by 
detecting positron-emitting radionuclides. 
The use of glycosylated NPs in imaging studies gives a better understanding of the role of 
carbohydrates in nature through CCIs and CPIs. Using different nanomaterials, the 
interaction between mannose functionalized fluorescent NPs and the lectin FimH that is 
present on the pili of E. coli was elucidated.111-112 Other studies give an insight of the 
interactions with more complex carbohydrates, such as between the cancer-associated 
glycosphingolipids sialosyllactosylceramide (GM3) present on melanoma cells and 
gangliotriaosylceramide (Gg3), present on lymphoma cells, that play an important role 
during the adhesion of melanoma cells to the endothelium in tumor metastasis.55 Sialyl 
LewisX functionalized NPs also served to image the endothelial inflammation during stroke 
as they interact with selectin proteins.113  
1.3.2. Drug delivery 
NPs have been widely used in drug delivery applications. Their high surface area permits 
drug loading enhancing the solubility and stability of the drugs. The conjugation of 
targeting moieties to NPs increases the therapeutic efficiency and lowers side effects. 
Moreover, the possibility to create multivalent interactions with the cell surface mimics the 
biological events occurring in nature. Drug conjugated nanoparticles show enhanced 
pharmacokinetics and tumor tissue accumulation due to the EPR effect.23 
A perfect nanocarrier should be biocompatible, have high drug loading capacities, have no 
premature drug release, be able to target the specific cells or tissues and display controlled 
drug release with an optimal effective local concentration.114 
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Targeted drug delivery allows for drug accumulation at a specific place independently of 
the drug administration method and route.115 Effective in vivo targeted drug delivery needs 
drug loading efficiency into the nanocarrier, but also an optimum blood half-life to ensure 
that the nanocarrier reaches the targeted place, and drug release within a timeframe where 
the drug is effective.116 Targeted drug delivery can be only achieved when there is 
overexpression of a specific marker on the targeted cell surface.116  
Carbohydrates can be used as targeting moieties that direct the drug loaded NPs to the place 
where they will carry out the therapeutic effect. Some cells overexpress lectins or 
carbohydrates that specifically interact with the carbohydrates conjugated to the NPs 
through CPIs and CCIs, respectively. Mannose receptors are overexpressed in cells of the 
immune system such as macrophages or dendritic cells.117 Galactose conjugated NPs can 
be used to target lectins such as asialoglycoprotein, which is overexpressed in liver cancer 
cells.118 Glucose is also known to be a transporter to the brain, and therefore shows potential 
for brain related diseases.119-120 
More complex carbohydrates such as Sialyl LewisX can be used to target the selectin family 
that are type I transmembrane glycoproteins containing an extracellular lectin domain.121 
These glycoproteins have a role in the adhesion process between platelets and leukocytes 











1.4. Aim of this thesis 
The objective of this dissertation is to contribute to the field of nanoparticle based imaging 
and drug delivery technologies for the treatment of different diseases. To achieve this goal, 
nanoparticle based carriers were designed and developed. The second step was the 
biological evaluation of the nanocarriers in vitro and in vivo, with a special focus on the 
imaging and drug delivery study of the targeted diseases. The protozoan parasites 
Plasmodium falciparum and Toxoplasma gondii were chosen in order to explore the use of 
nanotechnology for theranostics of these protozoan parasites. To further contribute to the 
improvement of cancer chemotherapy, tumor cells were targeted for both imaging and 
controlled drug delivery. 
The synthesis of ultrasmall gold nanoparticles using a thio-glycoside was explored to obtain 
biocompatible nanocarriers (Chapter 2). These ultrasmall nanoparticles show high potential 
in multimodal drug delivery due to the high surface area that can be exploited for multiple 
conjugations. Due to the presence of high cysteine domains on the surface of apicomplexan 
parasites, the developed nanoparticles can be used to study binding efficiency to these 
cysteine domains that could be further exploited for imaging and drug delivery applications 
of malaria and toxoplasmosis (Chapter 3). 
Mesoporous silica was used as drug delivery nanocarriers to investigate the synthesis of a 
different morphology that increases the cellular uptake (Chapter 4). Nanoparticle doping 
with disulfide moieties can lead to responsive breakable nanocarriers for controlled drug 
delivery with a special interest in cancer treatment. 
Finally, different glycosylated nanomaterials were synthesized to explore the biological 
activity of multivalent glycosylated scaffolds (Chapter 5). A better insight in brain targeting 
can be obtained that could be further utilized for imaging and drug delivery of brain related 
diseases. Also, more information about carbohydrate-protein interactions between 






2.	 Synthesis	 and	 characterization	 of	
glycosylated	 gold	 nanoclusters	 for	
biomedical	applications	
This chapter has been modified in part from the following article: 
Straightforward and robust synthesis of monodisperse surface-functionalized gold 
nanoclusters. S. Varela-Aramburu, R. Wirth, C.-H. Lai, G. Orts-Gil, P. H. Seeberger, 
Beilstein J. Nanotechnol. 2016, 7, 1278–1283.36 doi:10.3762/bjnano.7.118 
2.1. Introduction 
Nanoparticles, materials which range from 1 to 100 nm, are ideal tools to study biological 
processes.2, 72 Many different materials have been used to create nanoparticles as discussed 
in Chapter 1.21, 123-125 In particular, gold nanoparticles (AuNPs) are an attractive platform due 
to their biocompatibility, low toxicity, low immunogenicity,126 inherent optoelectronic 
properties,20 and high contrast in transmission electron microscopy (TEM). AuNPs are 
relatively easy to synthesize, functionalize and have tunable optical properties.8, 19, 21, 127-128 
Therefore, gold nanoparticles functionalized with carbohydrates,102 proteins,129 antibodies130 
and DNA,131 are commonly used as multivalent materials for biological studies. Some 
applications include the use of AuNPs in vivo when tagged with radiotracers,130, 132 for targeted 
delivery133 and, upon functionalization with carboxylic acids, to inhibit β-amyloid fibril 
growth during Alzheimer’s disease.134  
Several methods to synthesize gold nanoparticles have been reported. The most common 
method for producing spherical AuNPs is the reduction of chloroauric acid (HAuCl4) with 
sodium citrate under refluxing conditions.135 The appearance of a deep red color is indicative 
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of the formation of AuNPs. The size of the AuNPs is tunable from 10 to 100 nm by 
changing the concentration ratio of HAuCl4 to sodium citrate.  
Brust et al. described the synthesis of AuNPs based on a biphasic reaction using 
tetraoctylammonium bromide as a phase-transfer reagent that transports the gold ions from 
water to toluene.136-137 The gold ions are then reduced by NaBH4 in the presence of 
dodecanethiol. The group of Penadés improved this method by adding a thiol-terminated 
glycoconjugate to an aqueous solution of gold ions.138 Under these conditions, the reduction 
is performed in a single phase following the addition of NaBH4. 
Another promising method to synthesize AuNPs under reflux using 1-thioglucose as 
reducing and stabilizing agent,139 but the resulting 30 nm gold nanoparticles are too unstable 
to be used as biosensors.140 
Gold nanoclusters (NCs) are ultrasmall nanoparticles ranging between 1-3 nm. Their high 
surface area makes NCs ideal substrates for drug delivery applications.141 Several synthetic 
methods have been reported in the last 15 years focused on the synthesis of stable and 
monodisperse NCs. Nevertheless, most of these syntheses are tedious, time consuming and 
sensitive to reaction conditions such as temperature or even stirring speed.142-144  
The use of tetrakis(hydroxymethyl)phosphonium chloride (THPC) to reduce HAuCl4 under 
basic conditions145 or the use of NaBH4 in combination with cetyltrimethylammonium 
bromide (CTAB) as stabilizing agent are commonly used conditions for the preparation of 
NCs.146 
In an effort to create monodisperse, stable and surface-functionalized gold nanoclusters, 1-
thioglucose was explored as a reducing and stabilizing agent. A novel one-pot method to 
prepare gold nanoclusters using 1-thioglucose at room temperature was developed. This 
simple and robust method produces stable, and monodisperse nanoclusters. Oxidation of 
the carbohydrate results in NCs with carboxylic acid on the surface as determined by X-
ray photoelectron spectroscopy (XPS). Surface functionalization of NCs can be achieved 
through coupling to the carboxylic acids or addition of thiols. The resulting NCs are taken 
up by cells and are less cytotoxic than NCs prepared by other methods.  
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NCs were further functionalized with a chelator containing a radiotracer for in vivo 
biodistribution studies in mice using positron electron tomography (PET). Results showed 
the great potential of this new material for biomedical applications as the NCs accumulated 
in almost all the organs analyzed and were excreted after 24 h. 
2.2. Results 
2.2.1. Synthesis of glucose-based gold nanoclusters  
The addition at room temperature of 1-thioglucose as reducing agent to gold salts resulted 
in the formation of monodisperse gold NCs (Figure 2.1 a). Following this interesting 
observation, the influence of Au3+ to 1-thioglucose ratio on the yield and quality of the 
glucose-stabilized gold nanoclusters (Glc-NCs) was investigated (Table 2.1). Stable 
nanoclusters were synthesized when the ratio of gold to thioglucose was close to 1:1 (0.9:1 
– 1:1.4) (Figure 2.1 b). The nanoclusters aggregated within 5 h at very high gold ion to 1-
thioglucose ratios (1:0.5). At higher gold ion concentrations NCs were not fully coated with 
stabilizer and therefore more likely to collapse due to less steric hindrance. On the contrary, 
at high thioglucose concentrations NCs formation was not observed.  
 
Figure 2.1. a) Synthetic scheme of glucose-based gold nanoclusters (Glc-NCs); b) Glc-NCs using the 
reaction conditions shown in Table 2.1, freshly synthesized and after 5 h. Numbers correspond to the entries 
in Table 2.1. 
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Table 2.1. Synthesis optimization of Glc-NCs. 
 Ratio Au:1-thioglucose Observations 
1 1:0.2 Light brown (unstable) 
2 1:0.5 Dark-brown (unstable) 
3 1:0.9 Brown (stable) 
4 1:1.4 Brown (stable) 
5 1:1.9 Light brown (stable) 
6 1:2.4 White precipitate 
7 1:2.8 No reaction 
 
The morphology and size of the Glc-NCs were analyzed by high resolution TEM bright 
field imaging. The Glc-NCs have a monodisperse spherical shape with an average size of 
2.02 ± 0.18 nm, as determined by counting 110 nanoclusters (Figure 2.2). The size of the 
Glc-NCs was corroborated by hydrodynamic diameter measurements with dynamic light 
scattering (DLS) in aqueous solution (Figure 2.1 c).   
 
Figure 2.2. a) High resolution TEM bright-field image of Glc-NCs shows monodisperse nanoclusters, scale 
bar = 2 nm; b) Size distribution of Glc-NCs gives 2.02 ± 0.18 nm in diameter, counting 110 nanoclusters; c) 
Dynamic light scattering measurement of hydrodynamic diameter of Glc-NCs in MilliQ water. 
UV measurement of gold nanoparticles allows for the determination of particle size and/or 
shape.20, 147 As expected from gold nanoparticles smaller than 5 nm, no plasmon band was 
observed. The one-pot Glc-NC synthesis was temperature independent from 0-90 °C, as 
proved by the spectroscopic features of the different products (Figure 2.3). The only 
difference in the use of different temperatures during the synthesis was that at lower 
temperatures the nanocluster yield was slightly lower, as seen by the lower absorbance in 
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the UV spectra (absorbance 0.9 vs 1.1). In stark contrast to other known literature 
procedures142-144 this procedure is not strongly dependent on the reaction conditions offering 
a new simple and robust strategy for the production of gold nanoclusters.  
 
Figure 2.3. Ultraviolet spectra of Glc-NCs when synthesized at 0 °C and 90 °C. The absence of plasmon 
resonance in both spectra is indicative of similar shape and morphology. 
Glc-NCs were more stable than cetyltrimethylammonium bromide (CTAB-NCs) and 
tetrakis(hydroxymethyl)phosphonium chloride stabilized nanoclusters (THPC-NCs) as 
determined by UV absorbance measurements (Figure 2.4). Glc-NCs were stable and 
showed the same absorbance profile after three days of dialysis (Figure 2.4 c), whereas a 
plasmon band (indication of aggregation) was appearing for CTAB-NCs and THPC-NCs 
over a period of time (Figure 2.4 a, b). THPC-NCs did not show a plasmon resonance right 
after the synthesis, since the particle size was below 5 nm as shown by TEM, but after three 
days of dialysis the appearance of a band at 520 nm revealed nanoparticle aggregation 
(Figure 2.4 b). CTAB-NCs showed a plasmon band directly after synthesis, which is 
explained by the larger size and polydispersity of these nanoparticles, as shown by TEM 
imaging (Figure 2.4 c). This plasmon band shifted to longer wavelengths after three days, 
suggesting an increasing rate of aggregation. Moreover, TEM imaging of freshly 
synthesized Glc-NCs showed monodisperse nanoclusters, which was not the case when the 
nanoclusters were synthesized by the two other methods. The lack of stability of THPC-
NCs and CTAB-NCs could be due to the surface chemistry of the NCs as the stabilizers 




Figure 2.4. Ultraviolet spectra comparison of a) THPC-NCs, b) CTAB-NCs, and c) Glc-NCs freshly 
synthesized and after 3 days. TEM images of freshly synthesized NCs. 
The higher stability after dialysis could be explained if we consider that in Glc-NCs there 
is a strong binding between the thiol of the stabilizer and the gold surface, whereas in both 
CTAB-NCs and THPC-NCs the stabilizers are only adsorbed to the surface. Zeta (ζ) 
potential of the nanoclusters over dialysis time was measured to obtain the difference in 
surface potential between the dispersion medium and the stationary layer of fluid attached 
to the dispersed nanoclusters. The surface charge did not change upon dialysis for any 
sample as it stayed positive for CTAB-NCs and negative for both THPC-NCs and Glc-
NCs. It can be concluded that the surface chemistry of the nanoclusters does not change 
and the stabilizers remain attached (Figure 2.5). 




Figure 2.5. ζ potential measurement of Glc-NCs, THPC-NCs and CTAB-NCs upon time of dialysis against 
MilliQ water. 
To better understand the structure of the stabilizing agent in Glc-NCs, X-ray photoelectron 
spectroscopy (XPS) (Figure 2.6) was used. XPS allows for the surface chemical 
characterization of a material as it measures the elemental composition, empirical formula, 
chemical state as well as the electronic state of the elements located within 1-10 nm of the 
material. A typical XPS spectrum shows the binding energy that is calculated from the 
kinetic energy of the emitted electrons, that depends on the element, on the orbital from 
which the electron was extracted and the chemical environment of the atom. 
By analysing the XPS spectra, the gold core of the nanoclusters was confirmed by the Au4f 
scan (Figure 2.6 b) with a typical binding energy Au4f7/2 band at 83.52 eV ( 
Table 2.2). Moreover, S2p scan (Figure 2.6 e and  
Table 2.2) confirmed that the stabilizers were attached through an Au-S bond, as the binding 
energy S2p3/2 of thiol bound to gold gave a signal at 162.5 eV (Table 2.3). The O1s scan 
(Figure 2.6 c and  
Table 2.2) showed C-O (531.5 eV) and carbonyl (533 eV) binding energy bands on the 




Figure 2.6. X-ray photoelectron spectroscopy data of Glc-NCs. a) Survey scan of Glc-NCs. b) Au4f, c) O1s, 
d) C1s, e) S2p, elemental scans of Glc-NCs. 
 
Table 2.2. X-ray photoelectron spectroscopy data of Glc-NCs analysis from Figure 2.6. 
Element Peak BE FWHM eV Area (P) counts/s.eV 
C1s 284.8 3.29 802670.4 
O1s 531.59 3.02 1131512 
S2p 161.78 1.78 161929.7 
Au4f 83.52 2.82 2395402 
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The carbonyl signal is likely indicative of the oxidation of carbohydrate hydroxyls as 1-
thio-glucose precursor contains no carbonyl group. C1s scan confirms the previous 
observation by showing a possible carboxylic acid present in the stabilizing agent due to 
the presence of an O-C=O binding energy band at 288.5 eV (Table 2.3).  
Table 2.3. X-ray photoelectron spectroscopy analysis of Glc-NCs by chemical state. 
Chemical state Peak BE Chemical state Peak BE Chemical state Peak BE 
C-C 284.8 C-O 531.5 Au-S 162.5 
C-O-C 286 C=O 533   
O-C=O 288.5     
 
The IR showed the presence of some typical carboxylic acid bands such as the broad O-H 
stretching band at 3265 nm as well as a C=O stretching band at 1623 nm (Figure 2.7). This 
observation supports the hypothesis that the stabilizer contains a carboxylic acid due to the 
oxidation of the glucose in presence of the chloroauric acid. 
 
Figure 2.7. Infrared spectrum of Glc-NCs. 
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2.2.2. Surface modification strategies 
In this section, surface functionalization of the synthesized gold nanoclusters is described. 
Two different methods were used to modify the nanocluster surface: through a coupling 
reaction to the carboxylic acids of the stabilizers and via a further thiol substitution to the 
gold core. The two possible functionalization pathways open up opportunities to 
biofunctionalize Glc-NCs for many applications. 
2.2.2.1. Coupling reaction 
To confirm the XPS and IR analyses, a coupling reaction with trifluoroethanol was 
performed since the formation fluorine functionalized Glc-NCs (F@Glc-NCs) can be 
monitored by 19F-NMR. Different reaction conditions were tested to obtain the desired 
stable product (Table 2.4). A large excess of different coupling reagents was used to ensure 
that all the carboxylic acids present on the nanoclusters reacted. The treatment of the 
nanoclusters with most coupling reagents resulted in severe aggregation. Activation with 
both 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-
hydroxysulfosuccinimide (sulfo-NHS) yielded stable nanoclusters. The water solubility of 
the modified carboxylate decreases upon N-hydroxysuccinimide (NHS) whereas it 
increases with sulfo-NHS due to the charged sulfonate groups. Phosphate-buffered saline 
(PBS) at pH 7.2-7.5 was chosen as reaction medium (Scheme 2.1). The reaction gave stable 
nanoclusters upon treatment with both five and 20 equivalents of the coupling reagent, 
therefore, 20 equivalents were chosen for the synthesis to ensure complete conversion. 
 
Scheme 2.1. Functionalization of Glc-NCs by coupling trifluoroethanol to NC-surface carboxylic acid to 
yield F@Glc-NCs.  
 
Table 2.4. Reaction conditions for the synthesis of F@Glc-NCs. 
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Entry Coupling reagents (eq) Trifluoroethanol (eq) Solvents Observations 
1 EDC  + NHS  (200 eq) 200 Water:DMF (1:1) Aggregated 
2 EDC  + NHS  (50 eq) 50 Water:DMF (1:1) Aggregated 
3 EDC  + NHS  (5 eq) 200 Water:DMF (1:1) Aggregated 
4 EDC  + NHS  (5 eq) 200 Water Aggregated 
5 DIC  + NHS  (5 eq) 200 Water Aggregated 
6 EDC  + Sulfo NHS  (5 eq) 200 PBS (75 mM) Not aggregated 
7 EDC  + Sulfo NHS  (20 eq) 200 PBS (75 mM) Not aggregated 
 
After 30 min, 19F-NMR showed the appearance of the product peak along with the starting 
material (Figure 2.8 a). After dialysis for two days against milliQ water, only the product 
peak remained confirming the formation of the fluorinated product F@Glc-NCs (Figure 
2.8 b).  
 
Figure 2.8. a) 19F-NMR (400 MHz, H2O) spectrum after 5 min reaction showing one peak of the starting 
material and a small peak of F@Glc-NCs; b) 19F-NMR of F@Glc-NCs after dialysis showing one product 
peak. 
To calculate the number of active sites per nanocluster, an internal standard (IS) was used. 
Purified F@Glc-NCs were mixed with 2.7 µmol CsF as an internal standard in an NMR 
tube and 19F-NMR was measured (Figure 2.9). By integrating the peaks of the sample and 
the internal standard, it was possible to obtain the concentration of fluorine in F@Glc-NCs. 




Figure 2.9. 19F-NMR (400 MHz, H2O) of F@Glc-NCs with internal standard (CsF). The integration IS:-CF3 
was 1.00:0.13. 
The gold concentration in the sample (832 nmol) was determined by Inductively Coupled 
Plasma Atomic Emission Spectrometer (ICP-AES). Considering the concentration of gold 
and -CF3 in the sample, the number of gold atoms and -CF3 stabilizers in the NMR sample 
were calculated. 
To calculate the amount of -CF3 per nanocluster, the number of gold atoms in one 
nanocluster needs to be estimated. Therefore, the nanocluster was considered as a sphere 
with diameter 2 nm and density ρ = 19.3 g/cm3, using equation (1).  
𝑚 = /0 𝜋𝑟0𝜌  (1) 
From equation (1), the nanocluster mass obtained was 4.55·10-20 g which resulted in 139 
atoms per nanocluster, giving 20 -CF3/Nanocluster. 
Thus, it can be concluded that Glc-NCs can be functionalized via coupling to the carboxylic 
acid groups present on the surface and that there were 20 functionalities attached after 
completed conversion. 
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2.2.2.2. Thiol conjugation  
To further exploit the surface functionalization of Glc-NCs via a direct thiol linkage to the 
gold core, a pentylthiol mannoside was synthesized (Scheme 2.2). Peracetylated mannose 
1 was coupled with 5-chloropentanol in the presence of stoichiometric BF3.OEt2.The 
chloride was then converted to the acetylated thiol derivative 2 in the presence of KSAc.148 
Hydrolysis of the acetyl groups in basic conditions yielded the desired compound 3.149 
 
Scheme 2.2. Synthesis of pentylthiol mannoside 3. 
Pentylthiol mannoside 3 was incubated with Glc-NCs overnight at room temperature to 
yield Man@Glc-NCs (Scheme 2.3).  
 
 
Scheme 2.3. Glc-NCs functionalization via thio-substitution of pentylthiol mannoside on the gold surface 
giving Man@Glc-NCs.  
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After purification by dialysis, the IR spectrum revealed two new peaks corresponding to 
the stretch of the C-H bonds of the linker at 2955 and 2855 nm (Figure 2.10).  
 
Figure 2.10. Infrared spectrum of Glc-NCs (below in blue) and Man@Glc-NCs (above in black). The 
Man@Glc-NCs shows peaks of the C-H stretch from the linker.  
Man@Glc-NCs had the same monodisperse size and shape as non-functionalized Glc-
NCs, as observed by TEM. The nanocluster size of 2.061 ± 0.003 nm was averaged on 129 
counted nanoclusters (Figure 2.11). 
 
Figure 2.11. a) TEM image and b) size distribution of Man@Glc-NC considering 129 nanoclusters. The size 
of Man@Glc-NCs was 2.061 ± 0.003 nm. Scale bar = 20 nm. 
Chapter 2. Synthesis of glycosylated gold nanoclusters  
35 
 
Surface functionalization of mannose terminated linker on Glc-NCs (Man@Glc-NCs) was 
confirmed by performing an agglutination assay with mannose-binding lectin 
Concanavalin A (ConA). Only mannose functionalized nanoclusters were found to bind 
ConA, and aggregation was observed by the naked eye. Unfunctionalized Glc-NCs failed 
to aggregate since the oxidized thio-glucose was not recognized by ConA lectin (Figure 
2.12).  
 
Figure 2.12. Vials containing (1) Glc-NCs (2) Man@Glc-NC (3) Glc-NCs + ConA (4) Man@Glc-NCs + 
ConA. Aggregation is only observed upon addition of ConA lectin to the sample containing mannose 
functionalized gold nanoclusters (4). 
2.2.3. Cytotoxicity and cellular uptake  
The cytotoxicity of the nanocluster was assessed by incubating the nanoclusters for one day 
with the mouse cell line L929 as proof-of-concept study. Cell viability was measured using 
the MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium inner salt] assay.150 The cytotoxicity of Glc-NCs, CTAB-NCs and THPC-
NCs was compared showing that CTAB-NCs were toxic even at low concentrations (25 – 
0.2 µM), whereas both THPC-NCs and Glc-NCs did not show any toxicity even at the 




Figure 2.13.  Cellular cytotoxicity assay of a) Glc-NCs, b) THPC-NCs and c) CTAB-NCs after incubation 
for one day with L929 cell line. 
To test whether the free stabilizers were affecting the cytotoxicity, both Glc-NCs and 
THPC-NCs were incubated with the cells after synthesis without dialysis purification. Glc-
NCs did not show cytotoxicity at any concentration (Figure 2.14 a), whereas THPC-NCs 
were toxic at 100 µM resulting in a 60% drop in cell viability (Figure 2.14 b). Thus, Glc-
NCs are suitable for biological experiments even without purification. 
 
Figure 2.14. Cellular viability of a) Glc-NCs and b) THPC-NCs without purification after incubation of the 
nanoclusters for one day with L929 cell line. THPC-NCs without dialysis showed toxicity at 100 µM. 
To further explore the potential of Glc-NCs as nanocarriers, cellular uptake of the 
nanoclusters was studied by incubating 12.5 and 25 µM Glc-NCs with the same cell line. 
After 24 h, the cells were washed with PBS buffer and then treated with aqua regia to 
transform the gold nuclei into gold ions. ICP-AES confirmed that the Glc-NCs were cell 
permeable and 108-109 gold atoms per cell were detected (Figure 2.15). These results 
confirm the great potential of Glc-NCs for cellular delivery applications.  
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Figure 2.15. Cellular uptake of Glc-NCs when incubated with L929 cells for one day. An uptake of 108-109 
gold atoms per cell was measured with ICP-AES. 
A straightforward, robust and efficient one-pot method to prepare glucose-stabilized gold 
nanoclusters was developed. The resulting 2 nm nanoclusters are monodisperse and more 
stable than gold nanoclusters synthesized by other methods. Functionalization of the Glc-
NCs was achieved either via coupling to the carboxylic acid of the stabilizing agent or 
substitution with a thio-functionalized molecule. The Glc-NCs are non-toxic, and taken up 
by L929 cells. New opportunities for drug delivery applications will be described in 
Chapter 3. 
2.2.4. In vivo biodistribution using positron electron tomography 
(PET) 
Positron-emission tomography (PET) is a nuclear medicine imaging technique that 
monitors metabolic processes in the body. This technique is able to detect pairs of gamma 
rays that are emitted by a radiotracer, which is introduced into the body on a biologically 
active molecule.  
To better understand the metabolic fate of Glc-NCs, radiolabeling was chosen as it allows 
for sensitive, reliable ex and in vivo imaging with high temporal resolution. Copper-64 has 
favorable decay characteristics (t1/2 = 12.7 h, β+ = 19%; β = 40%; electron capture 40%) 
and has received significant attention in the PET field thanks to the well-established 
coordination chemistry of copper that allows for its complexation with a wide variety of 
chelators. These chelators can also be easily linked to biomolecules such as antibodies, 
proteins, peptides etc.151 The nanoclusters were functionalized with 2-S-(4-aminobenzyl)-
1,4,7-triazacyclononane-1,4,7-triacetic acid (p-NH2-Bn-NOTA) as ligand for 64Cu(II) 
because of the presence of carboxylic groups that would not change the negative surface 
charge of the pristine nanoclusters. 
2.2.4.1. Synthesis of NOTA functionalized gold nanoclusters 
Glc-NCs were firstly functionalized with p-NH2-Bn-NOTA to obtain NOTA@Glc-NCs 
as shown in Scheme 2.4. During this synthesis, several problems arose while trying to 
obtain stable NOTA functionalized nanoclusters. When the nanoclusters were 
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functionalized with a high concentration of p-NH2-Bn-NOTA, the nanoclusters aggregated. 
Hence, it is important to estimate the number of nanoclusters in the reaction solution (using 
UV or ICP-AES) in order to add the same amount of chelator ligands. This problem was 
solved by performing the conjugation reaction under sonication at 0 °C. Completion of the 
reaction was observed in 2 h using EDC and sulfoNHS as coupling reagents in the presence 
of PBS buffer. Dialysis against MilliQ water for two days was carried out to purify the 
nanoclusters for further characterization. 
 
Scheme 2.4. Conjugation of p-NH2-Bn-NOTA chelator to Glc-NCs to yield NOTA@Glc-NCs. 
The NOTA@Glc-NCs were characterized with IR by comparing the non-functionalized 
nanoclusters with the functionalized ones (Figure 2.16). The functionalized nanoclusters 
showed additional peaks from the chelator ligand such as C-H stretching (2919 cm-1), C=O 
(1730 cm-1) and C-O (1260 cm-1) from carboxylic acids present on the chelator, and C=O 
(1654 cm-1) from the amide bond formed during the reaction, which confirms the successful 
functionalization of the nanoclusters. 




Figure 2.16. IR spectra of pristine Glc-NCs (blue) and NOTA@Glc-NCs (black) 
TEM imaging of the purified NOTA@Glc-NCs showed the same size and morphology 
when compared to the pristine Glc-NCs (Figure 2.17).  
  
Figure 2.17. TEM image of purified NOTA@Glc-NCs. Scale bar = 20 nm. 
The samples were sent to the group of Dr. Holger Stephan at the Institute of 
Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden - Rossendorf 
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(HZDR) for biodistribution studies in a mouse model. NOTA@Glc-NCs underwent 
radiolabeling and accumulated in all the organs except for the brain. After 24 h, the 
nanoclusters were excreted in high amount, showing the high potential of this material for 
biomedical applications. 
2.2.4.2. 64Cu(II)-labeling and in vitro stabilitya 
The NOTA@Glc-NCs were labelled with 64Cu(II) to yield 64Cu(II)-NOTA@Glc-NCs 
(Figure 2.18) by adding 20 nmol gold nanocluster sample to 50 MBq of Cu[64Cu]Cl2 in 2-
[N-morpholino]-ethansulfonic acid (MES) buffer (pH 5.0) at 37 °C for 3 h. Subsequently, 
8-10 fold excess of EDTA was added to remove the unbound copper. Radio thin layer 
chromatography (radio TLC) chromatogram showed the successful radiolabelling of 
NOTA@Glc-NCs (Figure 2.19 a).  
 
Figure 2.18. Structure of 64Cu(II)-NOTA@Glc-NCs. 
The 64Cu(II)-NOTA@Glc-NCs were then purified using PD 10 size exclusion column by 
collecting 200 µL aliquots. Radio TLC chromatogram using instant thin layer 
chromatography with salicylic acid in citrate buffer at pH 5.0, showed that 64Cu(II)-
NOTA@Glc-NCs was further separated from unbound copper that formed a complex with 
citrate. The radiolabelling yield (RCY) of 64Cu(II)-NOTA@Glc-NCs was 46%. 
                                               
a Radiolabelling was carried out by Dr. Kritee Pant (Institute of Radiopharmaceutical Cancer Research, 
Helmholtz-Zentrum Dresden - Rossendorf (HZDR)). 




Figure 2.19. Radio TLC chromatograms of a) 64Cu(II)-NOTA@Glc-NCs after the reaction was completed 
and EDTA was added to capture unbound copper, and b) 64Cu(II)-NOTA@Glc-NCs after column 
purification using instant thin layer chromatography with salicylic acid in citrate buffer. 
The stability of the copper complex on 64Cu(II)-NOTA@Glc-NCs was assessed in serum 
in order to determine whether the radiotracer was released in biological medium over time. 
The 64Cu(II)-NOTA@Glc-NCs were purified using a PD 10 column and subsequently 
incubated with 1 mL of serum. Aliquots (150 µL) were taken at different time points and 
centrifuged using 10 kDa filters in order to calculate the bound/unbound copper on the 
sample. The complex was stable for the first 4 h and released only around 10% of copper 
after 24 h of incubation in serum (Figure 2.20). These results proved the stability of the 
copper complex on 64Cu(II)-NOTA@Glc-NCs and allowed for the injection of the 
material in mice for in vivo experiments. 
 
Figure 2.20. Analysis of copper release on 64Cu(II)-NOTA@Glc-NCs at different time points when 
incubated in serum. The low release of the radiotracer allows for the use in mouse experiments.  
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Radiometric titration was performed in order to obtain the concentration of copper in 
64Cu(II)-NOTA@Glc-NCs. An increasing amount of copper was added to 2 nmol of 
NOTA@Glc-NCs based on gold concentration. An excess of EDTA was added to remove 
the unspecific bound copper. The percentage of bound copper in 64Cu(II)-NOTA@Glc-
NCs was calculated as nmoles of copper added, giving 0.24 nmol of bound 64Cu per nmol 
of gold (Figure 2.21). 
 
Figure 2.21. Radiometric titration to calculate the bound copper in 64Cu(II)-NOTA@Glc-NCs. Results 
showed 0.24 nmol of bound 64Cu per nmol of gold in 64Cu(II)-NOTA@Glc-NCs. 
2.2.4.3. Biodistribution studiesb 
The fully characterized 64Cu(II)-NOTA@Glc-NCs were used for biodistribution studies 
in healthy Wistar rats. For the first experiment, the radiolabeling of NOTA@Glc-NCs was 
performed 3 h prior to injection in rats. To 64Cu(II)-NOTA@Glc-NCs, 1:5 mol excess of 
EDTA was added to remove the unspecifically bound copper and PD 10 size exclusion 
column was used to purify the sample. The 64Cu(II)-NOTA@Glc-NCs were then injected 
in healthy Wistar mice and biodistribution studies were performed in triplicates after 5 min, 
1 h and 24 h of injection. Even five minutes after injection, 64Cu(II)-NOTA@Glc-NCs 
were accumulated in many organs probably due to the optimum blood half-life (Figure 
2.22). The high accumulation of 64Cu(II)-NOTA@Glc-NCs in the kidneys can be 
                                               
b Biodistribution studies were carried out by the group of Dr. Holger Stephan group (Institute of 
Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden - Rossendorf (HZDR)). 
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explained with the excretion of around 7% of the injected dose (ID) through the urine after 
5 min, which is typical for ultrasmall nanomaterials (Figure 2.23).  
 
Figure 2.22. Whole-body biodistribution of 64Cu(II)-NOTA@Glc-NCs in healthy Wistar rats after 5 min, 
60 min and 24 h of injection. Radiolabelling was performed 3 h prior to injection. Data are represented as a 
percentage of injected dose per gram. 
Sixty minutes after injection, the biodistribution of 64Cu(II)-NOTA@Glc-NCs is similar 
to that five minutes after injection. The accumulation in the bone can be explained by 
affinity of 64Cu(II)-NOTA@Glc-NCs to hydroxyapatite or even to macrophages. A 
significant reticuloendothelial system (RES) uptake was observed, which can be explained 
with the high anionic charge of 64Cu(II)-NOTA@Glc-NCs that may increase uptake.152 
Overall, it was noticed that the accumulation in brain was negligible, since crossing the 





Figure 2.23. Elimination of 64Cu(II)-NOTA@Glc-NCs through the intestine (hepatobiliary) and urine 
(renal) after 5 min, 60 min and 24 h of injection. Radiolabelling was performed 3 h prior to injection. Data 
are represented as a percentage of injected dose per gram. 
It is important to notice that 1 h after injection, the 64Cu(II)-NOTA@Glc-NCs were 
accumulated in high amount in the liver. Nevertheless, 24 h after injection, the 
accumulation of 64Cu(II)-NOTA@Glc-NCs in the different organs was overall decreased 
(Figure 2.22), and almost 50% was excreted via hepatobiliary pathway in the feces (Figure 
2.23). Glc-NCs can be used for biomedical applications, for their accumulation capacity in 
many organs of the body (except for the brain) and for the ability to be cleared mostly from 
the body 24 h after injection. 
A second experiment was carried out by radiolabeling NOTA@Glc-NCs 24 h prior to 
injection. The results (Figure 2.24) did not coincide with the previous ones (Figure 2.22). 
Stirring for 24 h at room temperature after radiolabeling caused aggregation that was 
visually detected by the presence of black. The high accumulation of 64Cu(II)-
NOTA@Glc-NCs in lungs as well as in spleen and the low accumulation in all the other 
organs also can be explained by the particle aggregation (Figure 2.24).153  




Figure 2.24. Biodistribution of 64Cu(II)-NOTA@Glc-NCs in healthy Wistar rats after 5 min, 60 min and 24 
h of injection. Radiolabelling was performed 24 h prior to injection with no further purification. Data are 
represented as a percentage of injected dose per gram. 
Moreover, 64Cu(II)-NOTA@Glc-NCs were excreted in a much lower amount compared 
to the previous experiment. This can be clearly seen by the litter measurement after 24 h, 
that is much lower (around 9%) compared to the previous experiment (around 50%). In this 
second experiments the 64Cu(II)-NOTA@Glc-NCs were not cleared from the body as in 
the previous assay due to the presence of aggregates in certain organs that could not be 
excreted. To improve this, stability studies will be carried out in order to obtain a sample 
that could be stored after radiolabelling.  
Nevertheless, the first experiment showed that 64Cu(II)-NOTA@Glc-NCs has high 
potential to be applied in biomedical applications. As the nanoclusters are able to 
accumulate in many organs, the introduction of a targeting agent would direct the sample 
to a specific organ. Moreover, upon conjugation with a drug, the nanoclusters could be used 
for targeted delivery and thereby reduce side effects because of less administration and 




Figure 2.25. Elimination of 64Cu(II)-NOTA@Glc-NCs through the intestine (hepatobiliary) and urine (renal) 
after 5 min, 60 min and 24 h of injection. Radiolabelling was performed 24 h prior to injection with no further 
purification. Data are represented as a percentage of injected dose per gram. 
2.3. Conclusion and outlook 
In this chapter, a straightforward, robust and efficient one-pot method was developed to 
prepare glucose-stabilized gold nanoclusters. The resulting 2 nm nanoclusters do not 
possess a plasmon resonance, are monodisperse and more stable than gold nanoclusters 
synthesized by other methods (THPC and CTAB methods). Surface characterization 
analyses showed the presence of a carboxylic acid in the stabilizing agents due to the 
oxidation of thioglucose precursor. This carboxylic acid can be exploited for Glc-NCs 
functionalization via coupling with alcohols or amines. Further thiol conjugation on the 
gold core was achieved by the addition of a thiol functionalized carbohydrate. The pristine 
Glc-NCs showed no cytotoxicity and were able to penetrate L929 cells. In vivo studies in 
mice were performed in order to evaluate the bioaccumulation of Glc-NCs in different 
organs. For this purpose, Glc-NCs were radiolabeled with copper prior to injection. Results 
showed that radiolabeled Glc-NCs were able to reach and accumulate in all the organs 
except for the brain, and were also excreted after 24 h (almost 50% through the litter). Glc-
NCs hold great potential as nanocarriers that can be functionalized using different strategies 
and the carrier is neither biologically active nor cytotoxic.  
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A targeting moiety can be used to functionalize Glc-NCs together with a drug in order to 
create a bimodal system. In this way, the side effects of the drug will be reduced as fewer 
administrations are required. Since the Glc-NCs are excreted out of the body in a relatively 
short time, the plasma half-life could be increased by using different strategies such as 
changing the surface charge of the nanoparticles.154 
2.4. Experimental section 
2.4.1. General methods 
All reagents were commercially purchased and used without further purification. 
Anhydrous solvents were obtained from a Dry Solvent System (jcmeyer-solvent system). 
Air sensitive reactions were carried out using oven-dried glassware and under an 
atmosphere of argon or nitrogen. 
Thin-layer chromatography (TLC) was carried out on ALUGRAM® Xtra SIL plates pre-
coated with silica gel of 0.20 mm thickness (Macherey-Nagel). TLC spots were visualized 
either under UV irradiation (254/366 nm) or by dipping the TLC in sugar stain (0.1% (v/v) 
3-methoxyphenol, 2.5% (v/v) sulfuric acid in EtOH). Flash column chromatography was 
carried out using silica (Sigma Aldrich Silica Gel 60, 230 – 400 mesh). 
Lyophilized water containing samples were performed using an Alpha 2-4 LD Lyophilizer 
(Christ, Osterode am Harz, Germany). 
1H, 13C and 19F and two dimensional NMR data were obtained on Bruker ECX 400 MHz, 
Varian 400 MHz, Varian 600 MHz, and Bruker AVANCE III 700 MHz NMR 
spectrometers. 
FTIR spectra were recorded on a Spectrum 100 FT-IR spectrometer (Perkin Elmer). The 
samples were spotted as a solid on the detector before measurements. 
UV/Vis spectra were recorded on an UVmini-1240 UV/Vis spectrophotometer (Shimazu). 
Mass spectra were obtained using an electrospray ionization (ESI) interface on an Agilent 
LC/MSD TOF system. 
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Transmission electron microscopy (TEM) measurements were performed on a Zeiss EM 
912 Omega. The samples were prepared by immersion of grids into a small volume of the 
sample and subsequent solvent evaporation in a dust protected atmosphere. 
High resolution TEM imaging was performed using a Tecnai F20 X-Twin transmission 
electron microscope at GFZ Potsdam. The TEM is equipped with a field emission gun as 
electron emitter. TEM bright-field images were acquired as energy filtered images using a 
Gatan imaging filter GIF. A 20 eV window was applied to the zero-loss peak. Data were 
evaluated with the Gatan Digital Micrograph software package. 
Dynamic light scattering (DLS) measurements were carried out at a scattering angle of 
173° with a Malvern Zeta Nanosizer working at 4-mW He–Ne laser (633 nm). The Glc-
NCs were measured in MilliQ water. 
ζ potential was measured using a Malvern Zetasizer instrument in order to obtain the 
electrophoretic mobility of nanoparticles at different times of dialysis against MilliQ water. 
The Helmholtz-Smoluchowski equation was used to correlate the measured electrophoretic 
mobilities to the zeta potentials. Three replicates of each sample were measured six times 
at 25 °C in MilliQ water. 
X-ray Photoelectron Spectroscopy (XPS) measurements were carried out with a Thermo 
Scientific K-Alpha X-ray Photoelectron Spectrometer. A monochromatic AlKα radiation 
(hν = 1486.6 eV) was used. A 200 eV analyzer pass energy and a 1 eV energy step size 
were used in survey scan measurements. Element scans were performed with a 50 eV 
analyzer pass energy and a 0.1 eV energy step size. All the obtained binding energies were 
referenced to carbon 1s peak at 284.8 eV. The samples were prepared on gold thin film 
substrates. 
Inductively Coupled Plasma Atomic Emission Spectrometry (ICP-AES) for silicon 
concentration determination was performed on an Optima 8000; Perkin Elmer¸ 
Massachusetts; USA. Samples (1 mL) were diluted to a total volume of 10 mL using 
aqueous aqua regia. An external calibration series from 0.1 mg/L to 5 mg/L was prepared 
using Au standard solution. The average of 3 measurements was obtained and the initial 
dilution was back-calculated. 
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2.4.2. Synthetic chemistry methods 
2.4.2.1. Nanoparticle synthesis 
Glucose-based gold nanoclusters (Glc-NCs) 
 
1-thio-β-D-glucose sodium salt in MilliQ water (80.0 µL, 41.2 mM) was added to HAuCl4 
(1.0 mL, 2.9 mM) at room temperature. In a few seconds a change in color from yellow to 
brownish was observed indicating the formation of the gold nanoclusters. The solution was 
dialyzed in two cycles of 1.5 L of MilliQ water or filter centrifuged using Amicon Ultra 15 
mL tubes (3000g, 30 min, three times). 
THPC-based gold nanoclusters (THPC-NCs) 
 
As described previously,145 a solution of NaOH (1.5 mL, 0.2 M) was added to 45.5 mL of 
ultrapure water and stirred with the reducing agent tetrakis(hydroxymethyl)phosphonium 
chloride (THPC, 1 mL of a solution of 0.3 mL of 80% aqueous solution diluted to 25 mL 
with ultrapure water). The mixture was stirred for 5 min before the addition of HAuCl4 (2 
mL, 25 mM). The solution turned to a brown-orange color. The nanoclusters were further 





CTAB-based gold nanoclusters (CTAB-NCs) 
 
As described previously,146 10 mL of a solution of gold nanoclusters, HAuCl4 (250 nM) 
was mixed with cetyltrimethylammonium bromide (CTAB, 75 mM) and afterwards 
reduced by NaBH4 (600 nM). The reaction mixture was stirred for 5 min allowing the 
escape of the gas formed during the reaction. The nanoclusters were purified by two cycles 
of dialysis against 1.5 L of MilliQ water. 
Trifluoroethanol functionalized nanoclusters (F@Glc-NCs) 
 
A solution of Glc-NCs (1.0 mL, 0.4 µmol) was mixed with 1 mL of PBS. The resulting 
solution was diluted with MilliQ water to 10 mL and then 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC, 1.4 mg, 7.2 µmol) and N-
hydroxysulfosuccinimide  (sulfo-NHS, 1.6 mg, 7.2 µmol) were added under stirring. The 
reaction was allowed to stir for 5 min after which 2,2,2-trifluoroethanol (5.15 µl, 0.07 
mmol) was added and let react under stirring for 2 h. The F@Glc-NCs were purified twice 
against 1.5 L MilliQ water. 
Concentration of both gold and -CF3 in the NMR tube. 
NMR Tube Gold -CF3 
Concentration 832 nmol 117 nmol 
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Mannose functionalized nanoclusters (Man@Glc-NCs)  
 
To a solution of Glc-NCs (1.0 mL, 2.6 mM), the synthesized thio-linked mannose in MilliQ 
water (2.5 mg, 8.7 µmol) was added and the reaction was allowed to stir overnight at room 
temperature. The Man@Glc-NCs were dialyzed twice against 1.5 L of MilliQ water.  
2-S-(4-Aminobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) 
functionalized nanoclusters (NOTA@Glc-NCs) 
 
A solution of Glc-NCs (1.00 mL, 0.65 µmol Au, 1.26 1015 nanoclusters) was diluted with 
5 mL MilliQ water and 100 µL PBS. To this solution, EDC (2.50 mg, 0.01 mmol) and 
sulfo-NHS (2.80 mg, 0.01 mmol) were added dropwise and the reaction was allowed to stir 
for 5 min under sonication in an ice bath. Subsequently, an aqueous solution of 2-S-(4-
aminobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) (75.0 µL, 0.4 mmol) 
was added and allowed to react for 2 h under cold sonication bath. The NOTA@Glc-NCs 





Radiolabeling strategy (64Cu(II)-NOTA@Glc-NCs) 
To a solution of NOTA@Glc-NCs (20 nmol Au) Cu[64Cu]Cl2 (50 MBq) in 2-[N-
morpholino]-ethansulfonic acid (MES) buffer (pH 5.0) was added at 37 °C for 3 h. 
Subsequently, 8-10 fold of EDTA was added.  
The 64Cu(II)-NOTA@Glc-NCs were then purified using PD 10 size exclusion column by 
collecting 200 µL aliquots. The purified 64Cu(II)-NOTA@Glc-NCs were obtained at 3-4 
mL which was detected by radio thin layer chromatography. The RCY of 64Cu(II)-
NOTA@Glc-NCs was 46%. 
2.4.2.2. Carbohydrate synthesis 
(2R,3R,4S,5S,6S)-2-(acetoxymethyl)-6-((5-(acetylthio)pentyl)oxy)tetrahydro-2H-
pyran-3,4,5-triyl triacetate (2) 
 
Compound 1 (4.3 g, 11.1 mmol) was dissolved in anhydrous CH2Cl2 and 5-chloropentan-
1-ol (1.5 mL, 13.3 mmol) was added and the reaction stirred for 1 h. The mixture was 
cooled to 0 °C, BF3.OEt2 (6.4 mL, 51.2 mmol) was slowly added drop wise and the mixture 
continuously stirred for additional 12 h at room temperature under Argon atmosphere. The 
crude mixture was diluted with CH2Cl2 and water and the phases were separated. The 
organic layer was washed three times with saturated aqueous NaHCO3 and brine. The 
organic layers were combined, dried over sodium sulfate, filtered and concentrated in 
vacuum. The crude compound was taken to the next step without further purification. 
The crude compound (0.1 g, 0.2 mmol) was dissolved in anhydrous DMF and stirred with 
KSAc (0.5 g, 4.4 mmol) overnight at room temperature. The reaction mixture was extracted 
with EtOAc and concentrated in vacuum to obtain compound 2. The crude compound was 
purified using flash column chromatography (EtOAc/Hex 1:4) to obtain the desired 
compound (0.1 g, 95% yield over two steps). 
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1H NMR (400 MHz, CDCl3) δ 5.32 (dd, 1H, H-3), 5.27 (d, 1H, H-4), 5.21 (dd, J = 3.3, 1.7 
Hz, 1H, H-2), 4.78 (d, J = 1.4 Hz, 1H, H-1), 4.30 – 4.23 (m, 1H, H-6), 4.11 – 4.05 (m, 1H, 
H-6), 3.98 – 3.92 (m, 1H, H-5), 3.70 – 3.62 (m, 1H, CH2-7), 3.46 – 3.39 (m, 1H, CH2-7), 
2.86 (t, J = 7.3 Hz, 2H, CH2-11), 2.31 (s, 3H, CH3-SAc), 2.14 (s, 3H, CH3), 2.09 (s, 3H, 
CH3), 2.03 (s, 3H, CH3), 1.98 (s, 3H, CH3), 1.63 – 1.54 (m, 4H CH2-8,10), 1.46 – 1.37 (m, 
2H, CH2-9), NMR data were in good agreement with those previously reported.148 LC MS 




Compound 2 (50 mg, 0.1 mmol) was dissolved in 1 mL of MeOH, then sodium methoxide 
(5.5 mg, 0.1 mmol) was added and stirred for 2 h at room temperature. The reaction mixture 
was neutralized with amberlite-IR120 (H+) resin, filtered and concentrated in vacuum to 
obtain compound 3 (21.5 mg, 75% yield). 
1H NMR (400 MHz, CD3OD) δ 4.71 (s, 1H), 3.80 (d, J = 9.8 Hz, 1H), 3.76 (s, 1H), 3.72 
(d, J = 9.5 Hz, 1H), 3.70 – 3.66 (m, 1H), 3.65 (d, J = 3.5 Hz, 1H), 3.57 (t, J = 9.4 Hz, 1H), 
3.51 (d, J = 8.2 Hz, 1H), 3.44 – 3.37 (m, 1H), 3.33 (s, 2H), 2.68 (t, J = 7.1 Hz, 1H), 2.49 (t, 
J = 7.1 Hz, 2H), 2.13 (s, 1H), 1.70 (s, 1H), 1.66 – 1.53 (m, 4H), 1.48 (d, J = 7.7 Hz, 2H). 
NMR data were in good agreement with those previously reported.149 LC MS calculated 
for [M+Na]+ 305.1 C11H22O6S, found 305.4 
2.4.3. Biology methods  
Cell culture 
The mouse cell line L929 of adipose cells was cultured in 10 cm2 dishes with RPMI 1640 
+ 2 mM L-glutamine + 10% fetal bovine serum (FBS) + 0.26 µM cisplatin. The cells were 
incubated at 37 °C in an ambient air/5% CO2 atmosphere and sub-confluent cultures (70-




For the cell viability assessment, the cells were seeded at 13,000 cells/well in 96-well plates 
and allowed to settle overnight. Then, the cells were incubated with Glc-NCs at 500, 100, 
50, 25, 12.5, 6.250, 3.125, 1.563, 0.781, 0.391 and 0 mM from a concentrated stock solution 
of each of the Glc-NCs samples which was prepared in water and successively diluted in 
RPMI mixture cell media. For the controls, the same amount of water was added to the 
most concentrated samples and similarly diluted with the cell medium in order to see the 
effect of water on the viability of the cells. 
After 24 h, the CellTiter 96 AQueous One Solution Cell Proliferation Assay was used. For 
this assay, 20 µL of MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium inner salt] were directly added to the culture wells and 
incubated for 1-4 h. The absorbance was then measured at 490 nm using a 96-well plate 
reader. Untreated cells were assayed as a control reference. 
ICP-AES 
For gold uptake measurements, L929 cells were seeded in 10 cm2 plates. When cells 
reached confluence in the dish, the cell number was counted (approximately 9 × 107 cells 
per plate) and the Glc-NCs were added (gold concentrations: 12.5 µM, 25 µM). After 1 h 
treatment with Glc-NCs, the medium was removed and the cells were washed with DPBS 
+ 0.05% EDTA to collect cell residues. The cell residues were further digested with 300 
µL of HNO3:HCl (3:1) and decomposed for 48 h at room temperature. Subsequently, 700 
µL of MilliQ water was added to each tube. Gold concentrations were determined by 






Malaria is a mosquito-borne disease caused by a protozoan parasite that belongs to the 
Plasmodium species. There are five Plasmodium species that can infect humans, but 
Plasmodium falciparum (P. falciparum) is the most severe one. According to the World 
Health Organization (WHO), in 2015, 212 millions of malaria infected cases were reported 
worldwide, causing 429,000 deaths.155 The typical malaria symptoms are fever, headache 
and vomit, causing in severe cases seizures, yellow skin, coma or even death.  
The Plasmodium species, together with Toxoplasma gondii (T. gondii), belong to the 
phylum Aplicomplexa  having an apicoplast organelle and an apical complex structure that 
is important in the invasion process.156 Both Plasmodium and Toxoplasma species have a 
complex life cycle that involves different hosts. The life cycle of Plasmodium starts with 
the human host receiving Plasmodium sporozoites after the bite of an infected female 
Anopheles mosquito (Figure 3.1). These sporozoites are transmitted to the bloodstream and 
migrate to the liver within a few minutes where they undergo asexual maturation into liver 
merozoites during an asymptomatic period of six to 16 days. After this liver stage, the 
merozoites are released into the bloodstream and invade red blood cells (RBCs) starting 
the blood life cycle, where the malaria symptoms arise. This invasion of RBCs occurs 
mainly through an asexual erytrocytic cycle, but some of the merozoites undergo a sexual 
blood cycle (gametocytogenesis) and develop into male and female gametocytes. These 
gametocytes are then taken up by an Anopheles mosquito during a blood meal into the gut 
and develop into macrogametes (female) and microgametes (male). These gametes undergo 
fertilization resulting in a zygote formation that develops into an ookinete that migrates 
through the gut wall forming a polyploid oocyst. After maturation, this oocyst releases new 
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sporozoites that migrate to the salivary gland of the mosquito and are further transmitted to 
another human host through a mosquito bite, starting the cycle again. 
 
Figure 3.1. Life cycle of Plasmodium species. Plasmodium sporozoites are transmitted by a female Anopheles mosquito 
to the human host. These sporozoites migrate into the liver and develop into merozoites that are released to the 
bloodstream. Merozoites invade RBCs mainly through asexual reproduction releasing more merozoites, but also 
producing gametocytes that are taken up again by another Anopheles mosquito inside of which the life cycle is completed. 
Reprinted from Pasvol et al.157 Copyright (2016), with permission from Springer Nature. 
The malaria symptoms appear during the blood life cycle of P. falciparum. This 
erythrocytic cycle starts when the merozoites are released from the liver into the 
bloodstream.  The merozoites invade RBCs and undergo different stages as they start to 
reproduce asexually (Figure 3.2). The earliest stage inside the RBCs is called ring stage as 
the parasite adopts a ring shape. These rings further develop into early and late stage 
trophozoites that are visible under the optical light microscope due to an increase in size as 
well as by the beginning of polyploidy. Finally, the last polyploid stage of the blood life 
cycle is the schizont stage that, after 48 h of invasion, is capable to burst the RBC and 
release 16 to 32 merozoites, capable to invade other RBCs.158 The whole process of 
merozoites release, and further recognition, attachment and invading RBCs occurs very 
rapidly (less than a minute).156  
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During the blood life cycle, some of the parasites undergo gametocytogenesis, where they 
develop into gametocytes. This process increases under certain conditions such as high host 
parasitemia (quantitative content of parasites in the blood), or even drug treatment, as it 
creates an environmental stressor.159-160 In P. falciparum, the gametocytogenesis usually 
occurs within ten to twelve days and is divided into five stages (stages I to V). Gametocytes 
stage I are very similar to asexual trophozoites, but in stage II, the gametocytes start to 
elongate forming a D-shaped parasite (Figure 3.2). In stage III the gametocytes get longer 
reaching, in stage IV, a very elongated banana-like shape. Finally, in stage V of 
gametocytogenesis, both male and female gametocytes can be distinguished as the female 
gametocytes are more curved than the male ones.159  
 
Figure 3.2. Blood cycle of Plasmodium falciparum. The asexual cycle starts with RBCs invasion of merozoites and 
development of the parasites into different stages: rings, trophozoites, schizonts and finally merozoites that are released 
to the bloodstream to invade more RBCs. Some parasites undergo gametocytogenesis as they commit sexual development. 
The parasites undergoing different stages (I, II, III and IV) until they finally develop into stage V as male and female 
gametocytes. These gametocytes are further taken up by an Anopheles mosquito and are responsible for the transmission 
of the disease.  
Several methods to prevent and treat malaria exist, but are of limited efficacy.  Prevention 
methods of malaria comprise the use of insecticide treated nets, indoor residual spraying or 
even larva source management in order to eliminate malaria vectors. Nevertheless, the 
increasing resistance to insecticides requires the need of alternative methods to control 
malaria vectors.161 Regarding malaria treatments, the most effective medication is the 
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artemisinin-based combinational therapy (ACT) that uses the drug artemisinin together 
with other anti-malaria drugs. Artemisinin is extracted from sweet wormwood (Artemisia 
annua) that is cultivated in many countries of Asia and Africa. Nevertheless, the cultivation 
and production costs of artemisinin are relatively high, demanding the need of alternatives, 
such as chemical synthesis.162 Recently, a semi-synthetic approach was developed to 
produce artemisinin using a continuous-flow system.163 The starting material, artemisinic 
acid can be extracted from the same plant in higher yields allowing for a cost-effective 
large scale production. However, due to the low number of existing alternatives, the 
demand of novel efficient anti-malaria drugs is still high. Furthermore, the side effects of 
artemisinin (nausea, vomiting and dizziness) and other anti-malaria drugs, together with 
rising drug resistance due to high administrations suggest the need of other therapeutic 
strategies, such as targeted drug delivery.  
For targeted therapies, it is important to understand the surface biochemistry of the parasites 
during the blood cycle. It is known that the surface of merozoites is coated with 
glycosylphosphatidylinositol (GPI)-anchored proteins that are likely to play an important 
role during erythrocyte invasion.164 Many of these GPI-anchored surface proteins contain 
cysteine-rich domains, such as the reticulocyte binding homolog 5 (PfRh5), or the cysteine-
rich protective antigen (CyRPA).165-166 These cysteine-rich domains are known to also be 
expressed on the surface of other stages of P. falciparum such as schizonts, gametocytes 
and sporozoites.164, 167-168 Similarly, the asexual T. gondii stage tachyzoite has also surface 
proteins containing cysteine-rich domains, such as the surface antigen (SAG) related 
sequence (SRS) superfamily.156 Therefore, the design of a scaffold able to target cysteine 
could potentially give information regarding the proteins on each stage of P. falciparum 
and T. gondii. Moreover, the use of multivalent scaffolds such as nanoparticles, allows for 
the design of a multimodal system that can carry one or more biologically active functional 
groups. 
Thiols have been widely used to functionalize gold nanoparticles as the resulting bond is 
strong and useful for many applications such as sensing and drug delivery.169 In particular, 
cysteine has been used to functionalize gold nanoparticles.170-173 Nevertheless, there is no 
report about the use of gold nanoparticles to target cysteine moieties expressed on 
biological systems.  
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In this chapter, glucose-synthesized gold nanoclusters (Glc-NCs, Chapter 2) were used for 
targeting studies using Plasmodium falciparum and Toxoplasma gondii. For this purpose, 
Glc-NCs were used without further functionalization and conjugated with a dye to have a 
better insight into the binding efficiencies to the different stages of the protozoan parasites. 
Glc-NCs were further functionalized with pyrimethamine, a drug used to treat both malaria 
and toxoplasmosis, to further determine the effectiveness of this system as a nanocarrier.174-
175 
3.2. Results 
3.2.1. Targeting Plasmodium falciparum 
As described in Chapter 2, Glc-NCs showed high potential for biomedical applications. To 
assess the suitability of Glc-NCs to target Plasmodium falciparum different biological 
experiments were carried out using in vitro P. falciparum cultures.  
Mature stages in the erythrocytic cycle of P. falciparum contain cysteine-rich domains on 
the parasite surface.  As cysteine is widely used to functionalize gold nanoparticles 
(AuNPs), to get a first insight into the possibility of using gold nanomaterials for targeting 
cysteine-rich domains, extracellular schizonts were treated with 2 nm Glc-NCsc and citrate 
stabilized AuNPs (Cit-AuNPs) of 20 nm (Figure 3.3). Cit-AuNPs were synthesized using 
the previously reported Turkevich method.135  
 
                                               
c Synthesis of Glc-NCs was performed as described in Chapter 2. 
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Figure 3.3. Transmission electron microscopy images of Glc-NCs (left) and Cit-AuNPs (right). Scale bar = 50 nm. 
Inductively Coupled Plasma Atomic Emission Spectrometry (ICP-AES) was used to detect 
the concentration of gold bound to the parasites. Schizonts were isolated from RBCs by 
incubating a culture with high parasitemia at schizont stage with saponin to lyse RBCs. 
Three different concentrations of Glc-NCs and Cit-AuNPs in PBS (5, 20 and 50 µM, based 
on atomic gold) were incubated with the isolated parasites for 15 min at room temperature. 
After incubation, the parasites were washed three times with PBS to remove unbound 
nanoparticles and incubated for 24 h with aqua regia, to oxidize Au(0) to Au(III) that was 
detected by ICP-AES. The binding efficiency of Glc-NCs was significantly higher at the 
three concentrations compared to the binding of Cit-AuNPs (Figure 3.4). This proves that 
gold nanoparticles adhere to mature parasites, possibly via cysteine-rich domains. 
Moreover, the higher binding of Glc-NCs compared to Cit-AuNPs can be explained due 
to size, as the smaller the nanoparticles, the higher the surface area. This provides a higher 
surface contact with the parasites allowing for more Glc-NCs to bind, which results in a 
higher binding efficiency. This result shows the high potential of using gold as targeting 
nanovector of P. falciparum, especially in the ultrasmall range, as the high surface to 
volume ratio also affords more surface area for bioconjugations.  
 
Figure 3.4. Binding efficiency of Glc-NCs (2 nm) and Cit-AuNPs (20 nm) in three different concentrations based on 
atomic gold (5, 20 and 50 µM) to extracellular schizonts. 
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The high binding efficiency of Glc-NCs to isolated mature parasites can be exploited to 
target parasites present inside RBCs. Glc-NCs are not cytotoxic in mouse fibroblast cells 
and biodistribute well in vivo (Chapter 2). Nevertheless, Glc-NCs should show as well 
minimum hemolytic effect for further in vitro experiments. For this purpose, a hemolysis 
assay was performed using different concentrations of Glc-NCs (ranging from 2.5 nM to 
50 µM, based on atomic gold) with human RBCs invaded by parasites at different stages 
(i.e. rings, trophozoites and schizonts), as well as healthy RBCs were taken as control.   
The three different blood stages of P. falciparum were isolating by performing either 
sorbitol synchronization to isolate ring stages or percoll synchronization or using magnetic 
columns to isolate schizont stages. Sorbitol synchronization takes advantage of the osmotic 
fragility of malaria-infected RBCs and is able to selectively lyse erythrocytes containing 
mature parasites.176 Schizont stages can be magnetically separated because during the blood 
life cycle, the parasites degrade the hemoglobin of the RBCs as a main source of amino 
acids which results in an accumulation of haem in the cells.177 This free haem is 
metabolized and converted into malaria pigment haemozoin, which forms paramagnetic 
iron crystals that are accumulated in the vacuole of mature parasites. Since the haem moiety 
in the hemoglobin is diamagnetic, the iRBCs containing only mature parasites can be 
separated using magnetic-activated cell sorting (MACS) and LD columns. 
To understand whether the parasitemia affects the hemolysis of RBCs incubated with Glc-
NCs, the experiment was performed using 1% and 10% parasitemia of highly synchronized 
cultures. For this experiment, infected and healthy RBCs were incubated with Glc-NCs at 
different concentrations for 15 min. Subsequently, the samples were centrifuged and the 
supernatant was separated and measured at 540 nm to obtain the amount of lysed RBCs. 
Hemolysis was calculated by considering 100% of lysis RBCs treated with saponin, and 
0% of lysis RBCs incubated with PBS. Glc-NCs did not produce significant hemolysis, as 





Figure 3.5. Hemolysis assay performed by incubating different concentrations of Glc-NCs (2.5 nM – 50 µM) with 1% 
and 10% parasitemia of highly synchronized cultures (rings, trophozoites and schizonts) and healthy RBCs. 
To further assess the binding capabilities to different P. falciparum blood stages, Glc-NCs 
were conjugated with a fluorescent dye containing a free primary amine (ATTO647N) to 
yield ATTO@Glc-NCs (Scheme 3.1).d  
 
Scheme 3.1. Conjugation of the fluorescent dye ATTO647N to Glc-NCs to yield ATTO@Glc-NCs. 
After dialysis purification for 2 days, transmission electron microscopy (TEM) of 
ATTO@Glc-NCs showed same particle size and shape as naked Glc-NCs (Figure 3.6 c). 
UV spectra showed an absorbance band at around 640 nm in ATTO@Glc-NCs, 
confirming the presence of the dye on the surface of the nanoclusters (Figure 3.6 a, b).  
                                               
d Optimized conditions used for the coupling reaction are described in Chapter 2. 
 




Figure 3.6. a) UV spectrum of naked Glc-NCs; b) UV spectrum (above) of ATTO@Glc-NCs that shows a band at 640 
nm that corresponds to the absorption band of ATTO647 dye (below); c) TEM of ATTO@Glc-NCs. Scale bar = 20 nm. 
To test whether ATTO@Glc-NCs were able to specifically bind parasites, nanoclusters 
(20 µM) were incubated for 15 min with both infected and healthy RBCs. Subsequently, 
the unbound ATTO@Glc-NCs were washed out with PBS buffer and the parasites were 
stained with the DNA binding dye 4',6-diamidino-2-phenylindole (DAPI, in blue), as RBCs 
do not contain DNA, unless they are invaded by P. falciparum parasites. Confocal laser 
scanning microscopy (CLSM) showed that ATTO@Glc-NCs (in red) were specifically 
binding P. falciparum parasites (in blue) and not RBCs (Figure 3.7). RBCs were identified 




Figure 3.7. Confocal laser scanning microscopy of ATTO@Glc-NCs (red) at 20 µM incubated with a) P. falciparum 
infected RBCs, and b) healthy RBCs (blue = DAPI). Scale bar = 5 µm. 
In order to verify that the nanoclusters are binding due to the gold core and not through the 
dye, another control experiment was carried out using the corresponding concentration of 
non-conjugated ATTO647N dye conjugated on ATTO@Glc-NCs. Both healthy and 
infected RBCs were incubated for 15 min with the ATTO647N dye and further washed 
with PBS buffer to remove unbound material. Parasites were further stained with DAPI and 
measured with CLSM. Results showed that the free ATTO647N dye (in red) did not bind 
the parasites or the healthy RBCs (Figure 3.8). 
 
 




Figure 3.8. Confocal laser scanning microscopy of free ATTO647N (red) incubated with a) P. falciparum infected RBCs 
(scale bar = 20 µm), and b) healthy RBCs (blue = DAPI). Scale bar = 10 µm. 
To further prove that the binding of ATTO@Glc-NCs occurs through the gold core and 
not due to the dye, the fluorescent dye cyanine 5 (Cy5) containing a free amine was used 
to tag Glc-NCs using the same conditions to yield Cy5@Glc-NCs (Scheme 3.2) 
 
Scheme 3.2.  Conjugation of the fluorescent dye Cy5 to Glc-NCs to yield Cy5@Glc-NCs. 
After further dialysis purification, transmission electron microscopy (TEM) of Cy5@Glc-
NCs showed same particle size and shape as naked Glc-NCs as well as ATTO@Glc-NCs 
(Figure 3.9 c). UV spectra showed an absorbance band at around 640 nm in Cy5@Glc-






Figure 3.9. a) UV spectrum of naked Glc-NCs; b) UV spectrum (above) of Cy5@Glc-NCs that shows a band at 640 nm 
that corresponds to the absorption band of Cy5 dye (below); c) TEM of Cy5@Glc-NCs. Scale bar = 20 nm. 
Similarly as described for ATTO@Glc-NCs, to analyze whether Cy5@Glc-NCs were able 
to specifically bind parasites, 20 µM of the tagged nanoclusters were incubated for 15 min 
with both infected and healthy RBCs. The unbound Cy5@Glc-NCs were washed out with 
PBS buffer and the parasites were stained with DAPI (in blue). CLSM showed specific 
binding of Cy5@Glc-NCs to the parasites and no the RBCs. 
 
Figure 3.10. Confocal laser scanning microscopy of Cy5@Glc-NCs (green) at 20 µM incubated with a) P. falciparum 
infected RBCs (scale bar = 5 µm), and b) healthy RBCs (blue = DAPI). Scale bar = 10 µm. 
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Similarly to the ATTO647N dye experiments, a control experiment was carried out 
incubating the corresponding concentration of Cy5 dye conjugated to Cy5@Glc-NCs using 
the sample conditions as previously described. CLSM imaging showed that the free Cy5 
dye has unspecific affinity to P. falciparum parasites as well as some healthy RBCs (Figure 
3.11). Therefore, for further experiments, ATTO647N dye was used to tag Glc-NCs. 
 
Figure 3.11.  Confocal laser scanning microscopy of free Cy5 (green) incubated with P. falciparum infected RBCs (blue 
= DAPI). Scale bar = 5 µm. 
To analyze the specificity of Glc-NCs to target the different blood stages of P. falciparum, 
the infected cultures underwent different types of synchronization cycles to isolate the 
specific stages. Ring stages were obtained by performing the sorbitol synchronization. 
Schizonts were isolated by doing either percoll synchronization or magnetic cell separation 
using columns and a magnetic-activated cell sorting (MACS). Trophozoites (both early and 
late stages) were imaged 22 to 36 h after performing sorbitol synchronization. Each of the 
synchronized cultures was incubated with 20 µM ATTO@Glc-NCs for 15 min. Healthy 
cells were also treated as control. After washing with PBS to remove unbound 
ATTO@Glc-NCs, CLSM was used to image the specific binding to all the different 
asexual blood stages. Results showed that ATTO@Glc-NCs were able to specifically bind 
all the asexual blood stages: rings, early and late trophozoites and schizonts (Figure 3.12). 
This binding specificity to all the asexual blood stages can be important for drug delivery, 





Figure 3.12. Confocal laser scanning microscopy of synchronized cultures containing rings, early and late trophozoites, 
and schizonts incubated with ATTO@Glc-NCs (red), show specific binding to each asexual blood stage (blue = DAPI). 
Scale bar = 2 µm. 
Cysteine-rich domains are known to be present on the parasite surface of schizonts.164 In 
order to analyze the location of ATTO@Glc-NCs on mature parasites, Z-Stack confocal 
imaging was performed on schizonts incubated with ATTO@Glc-NCs using the same 
conditions as previously described. Results showed that ATTO@Glc-NCs are covering 
the surface of the mature parasites, but are also present inside the parasite, as also DAPI (in 
blue) was co-localized with the tagged nanoclusters (in red) (Figure 3.13). This proves that 
ATTO@Glc-NCs not only interact with the surface through the cysteine rich domains, but 
are also able to penetrate the parasite and accumulate inside of it. 




Figure 3.13. Z-stack confocal imaging of a schizont incubated with ATTO@Glc-NCs (red) (blue = DAPI). Scale bar = 
2 µm. 
The transmission of the malaria disease occurs through the sexual blood stages. 
Gametocytogenesis can be also induced in an in vitro culture under very specific conditions 
that involve high levels of parasitemia, low hematocrit to simulate anemia, and the presence 
of human serum and N-acetyl-glucosamine in the parasite culture medium.178 Isolation of 
all the different stages of the sexual blood cycle (stages I to V) was achieved either by 
percoll synchronization or magnetic cell separation using LD columns to separate the late 
stages from the early ones. ATTO@Glc-NCs were once again incubated for 15 min. After 
washing with PBS, CLSM was used to monitor the binding of ATTO@Glc-NCs to the 
different sexual stages. ATTO@Glc-NCs bind all the stages from I to IV and even the 
isolated male and female gametocytes (stage V), which is essential for delivery of drugs 
against gametocyte stages that prevents the transmission of the malaria disease through the 




Figure 3.14. Confocal laser scanning microscopy of synchronized cultures containing gametocytes stages I, II, III, IV 
and V incubated with ATTO@Glc-NCs (red), show specific binding to each sexual blood stage (blue = DAPI). Scale 
bar = 2 µm for stages I-III. Scale bar = 5 µm for stages IV and V. 
Gametocytes in stage IV were also analyzed by Z-stack imaging in confocal microscopy 
after incubation with ATTO@Glc-NCs.  Results show that ATTO@Glc-NCs interact 
with the surface of the parasite, but are also present inside the parasite, as the signal of the 
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tagged nanoclusters (in red) co-localizes with the signal of the nuclei of the parasites (in 
blue) (Figure 3.15). 
 
Figure 3.15. Z-stack confocal imaging of a gametocyte stage IV incubated with ATTO@Glc-NCs (red) (blue = DAPI). 
Scale bar = 5 µm 
The ability of Glc-NCs to specifically target all the blood stages of P. falciparum opens up 
opportunities for targeted drug delivery applications. Conjugation of drugs on Glc-NCs 
was done for further delivery studies. 
3.2.2. Targeting Toxoplasma gondii 
Similarly to P. falciparum, the protozoan parasite T. gondii also contain cysteine rich 
domains on surface proteins.156 Thus, ATTO@Glc-NCs were used to target T. gondii.e  
Extracellular parasites were used to assess the binding of ATTO@Glc-NCs with CLSM. 
For this experiment, the tagged nanoclusters were incubated for 15 min with extracellular 
T. gondii in the tachyzoite stage, and further washed with PBS to remove unbound 
nanoclusters. CLSM imaging showed that the cysteine rich domains on the parasite surface 
could probably be targeted by ATTO@Glc-NCs (Figure 3.16). The parasites could be 
identified from the DIC and the DAPI (in blue) channel.  
                                               
e Toxoplasma gondii parasites (extracellular and intracellular) were provided by Ms. Laura Radtke, Humboldt 




Figure 3.16. Confocal laser scanning microscopy of ATTO@Glc-NCs (red) incubated with extracellular T. gondii (blue 
= DAPI). Scale bar = 2 µm. 
CLSM Z-stack imaging was performed to obtain more information about the location of 
ATTO@Glc-NCs on the parasites. The nanoclusters were found on the surface of the 
extracellular parasites, but were also located inside, as the nuclei (in blue) co-localized with 
the signal of the ATTO@Glc-NCs (in red) (Figure 3.17). 
 
Figure 3.17. Z-stack confocal imaging of extracellular T. gondii parasites incubated with ATTO@Glc-NCs (red) (blue 
= DAPI). Scale bar = 2 µm. 
Human foreskin fibroblast (HFF) cells were infected with T. gondii to assess whether 
ATTO@Glc-NCs were able to penetrate the cells and target the parasites. The infected 
cells were grown in glass slides and the previously described conditions (Section 3.2.1.) 
were used for the binding assay of ATTO@Glc-NCs. DAPI (in blue) was used to stain the 
nuclei of both host cells and parasites, SAG1 (in green) is a tagged antibody that specifically 
binds SAG surface proteins, and was used to identify the intracellular parasites. CLSM 
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analysis was carried out to analyze the binding of the nanoclusters in a much more complex 
environment. Confocal imaging showed that HFF host cells were infected with cysts 
containing bradyzoites. These parasites could be directly identified through the SAG1 
channel (in green) as well as the DAPI channel (in blue).f The nuclei of the host cells were 
much bigger in size compared to the nuclei of the parasites. Results showed that 
ATTO@Glc-NCs were dispersed within the host cell and were also attached to the 
bradyzoites (Figure 3.18). The attractiveness of targeting bradyzoites lies in the formation 
of cysts that accumulate in many organs such as lungs, liver, kidneys and are also able to 
reach the brain.179 Interestingly, it is possible to visualize the cyst that contains the 
bradyzoites, as it is formed by a vacuole, where the ATTO@Glc-NCs are not attached to. 
This means that ATTO@Glc-NCs are able to penetrate the vacuole, but do not bind to it. 
The presence of ATTO@Glc-NCs overall within the cells can be explained by the host 
cellular uptake that retains the nanoclusters for a long time before they are exocytosed.  
 
Figure 3.18. Confocal laser scanning microscopy of ATTO@Glc-NCs (red) incubated with T. gondii infected HFF cells 
(blue = DAPI, green = SAG1). Scale bar = 5 µm. 
To gain a better understanding of the exact location of the ATTO@Glc-NCs within the 
infected HFF cells, Z-stack confocal analysis was performed. ATTO@Glc-NCs are 
localized on the surface and inside the bradyzoites, which can be confirmed as the SAG1 
antibody stains only the surface of the parasite (Figure 3.19). It is also possible to confirm 
that the vacuole containing the bradyzoites does not have affinity to ATTO@Glc-NCs, as 
there is a gap line between the bradyzoites and the rest of the cytoplasm.  
                                               
f Microscopy slides preparation was performed by Ms. Laura Radtke, Humboldt University, Department of 




Figure 3.19. Z-stack confocal imaging of T. gondii infected HFF cells incubated with ATTO@Glc-NCs ) (red) (green = 
SAG1). Scale bar = 5 µm. 
3.2.3. Drug conjugation to Glc-NCs 
Pyrimethamine is a drug used to treat both malaria and toxoplasmosis as it is active against 
both protozoan parasites.174-175 Conjugation and quantification of pyrimethamine on Glc-
NCs was carried out for further inhibition studies against P. falciparum and T. gondii. 
Conjugation of pyrimethamine was performed through an amine-carboxylic acid coupling 
reaction, using the same conditions previously described (Chapter 2). Excess of drug was 
added to ensure the complete coverage of the nanocluster surface to yield Pyr@Glc-NCs 
(Scheme 3.3).  
 
Scheme 3.3. Conjugation of the drug pyrimethamine to Glc-NCs to yield Pyr@Glc-NCs. 
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After dialysis purification, zeta (ζ) potential showed a decrease in the surface charge from 
-30 mV to -15 mV, due to drug functionalization through the carboxylic acid stabilizers 
(Figure 3.1).  
 
Figure 3.20. Zeta potential of Glc-NCs and Pyr@Glc-NCs show a difference in the surface charge due to drug 
conjugation. 
Drug loading was quantified for further biological experiments. The UV spectrum of free 
pyrimethamine presented a band with a maximum at 211 nm (Figure 3.21).  
 
Figure 3.21. UV spectrum of free pyrimethamine that presents a maximum band at 211 nm. 
A calibration curve was obtained by preparing stock solutions of pyrimethamine in DMSO 
in the concentration range from 0 to 1.25 µg/mL and measuring UV absorbance at 211 nm. 
A trendline was fit to the values giving an equation that could be further used to interpolate 






















Figure 3.22. Calibration curve obtained by measuring the absorbance of free pyrimethamine at different concentrations 
(0 - 1.25 µg/mL) at 211 nm. 
The absorbance value for pyrimethamine loading was calculated by subtracting the total 
signal of Pyr@Glc-NCs from that measured by only the Glc-NCs. To this end, the 
absorbance values of a sample of pristine Glc-NCs, prepared at equal concentration, were 
recorded as the control. The concentration of atomic gold can be quantified at 400 nm.180 
UV spectra showed a difference in the absorbance of the two bands at 211 nm that 
corresponded to the loading of pyrimethamine (Figure 3.23). 
 
Figure 3.23. UV spectra of Glc-NCs and Pyr@Glc-NCs at same concentration (based on gold). The absorbance 
difference at 211 nm corresponds to the pyrimethamine loading in Pyr@Glc-NCs. 
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After interpolating in the calibration curve (Figure 3.22), the loading of pyrimethamine on 
Pyr@Glc-NCs was found to be 5 µg of pyrimethamine per µmol of atomic gold. 
The drug loaded nanoclusters are currently being assessed in vitro with P. falciparum 
cultures, using free pyrimethamine in the same concentration range as control, in order to 
test whether targeted drug delivery permits the use of less quantities of drug.   
3.3. Conclusion and Outlook 
The protozoan parasites P. falciparum and T. gondii were targeted by gold nanoparticles 
through the high cysteine domains contained in the surface proteins of both parasites. The 
small size of Glc-NCs allowed for more accumulation on extracellular P. falciparum 
parasites compared to bigger gold nanoparticles. Glc-NCs were further tagged with a 
fluorescent dye for imaging studies. Confocal microscopy imaging showed that Glc-NCs 
were able to target both asexual and sexual blood stages of P. falciparum, but were not 
accumulating in healthy red blood cells. 
Glc-NCs were able to bind and penetrate extracellular T. gondii parasites as shown by 
confocal microscopy. Glc-NCs were also able to target T. gondii inside human foreskin 
fibroblasts. Nevertheless, accumulation inside the host cells was also observed. 
Glc-NCs were conjugated to the drug pyrimethamine that is active against P. falciparum 
and T. gondii. The pyrimethamine loaded Glc-NCs will be further used for inhibition 
experiments against both parasites both in vitro and in vivo. 
3.4. Experimental part 
3.4.1. General methods 
All reagents were commercially purchased and used without further purification.  
Transmission electron microscopy (TEM) measurements were performed on a Zeiss EM 
912 Omega. The samples were prepared by immersion of grids into a small volume of the 
sample and subsequent solvent evaporation in a dust protected atmosphere. 
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UV/Vis spectra were recorded on Shimadzu UV-3600 spectrophotometer double-beam 
UV–VIS–NIR spectrometer and baseline corrected.  
ζ potential was measured using a Malvern Zetasizer instrument in order to obtain the 
electrophoretic mobility of nanoparticles at different times of dialysis against MilliQ water. 
The Helmholtz-Smoluchowski equation was used to correlate the measured electrophoretic 
mobilities to the zeta potentials. Three replicates of each sample were measured six times 
at 25°C in MilliQ water. 
Confocal Microscopy imaging was performed with a Zeiss LSM 710 confocal microscope 
system equipped with a 63x magnification, numerical aperture 1.3 of Zeiss LCI Plan-
NEOFLUAR water immersion objective lens (Zeiss GmbH, Germany). 
Flow Cytometry (FACS) analysis was acquired on a FACSCanto II flow cytometer (BD 
Biosciences, San Jose, CA, USA). Fluorescence of 10,000 living single cells was analyzed 
after monoparametric acquisition using the FITC Area parameter (excitation with a 488 nm 
Blue Laser, 585/42 nm emission filter). Data were analyzed with FlowJo analysis software 
(Tree Star Inc., Ashland, OR). 
Inductively Coupled Plasma Atomic Emission Spectrometry (ICP-AES) for gold 
concentration determination was performed on an Optima 8000; Perkin Elmer¸ 
Massachusetts; USA. Samples were diluted to a total volume of 5 mL using aqueous aqua 
regia. An external calibration series from 0.1 mg/L to 5 mg/L was prepared using Au 
standard solution. The average of 3 measurements was obtained and the initial dilution was 
back-calculated. 
3.4.2. Synthetic chemistry methods 
Citrate stabilized AuNPs (Cit-AuNPs) 
 
As previously reported,135 a preheated solution of sodium citrate (10 mL, 1%) in MilliQ 
water was added to a solution of HAuCl4 (100 mL, 500 µM) in MilliQ water under boiling 
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conditions (100 ºC). No refluxing was used to prevent the presence of temperature gradients 
within the liquid. After 15 minutes, the red solution was cooled to room temperature. The 
resulting Cit-AuNPs were dialyzed against 1.5 L MilliQ water three times. 
ATTO tagged Glc-NCs (ATTO@Glc-NCs) 
 
A solution of Glc-NCs (5.0 mL, 1.4 µmol Au, 6.11 1015 nanoclusters) was diluted with 25 
mL MilliQ water and 500 µL PBS. To this solution, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC, 6.5 mg, 34 µmol) and N-
hydroxysulfosuccinimide  (sulfo-NHS, 7.4 mg, 34 µmol) were added dropwise and the 
reaction was allowed to stir for 5 minutes under sonication in an ice bath. Subsequently, an 
aqueous solution of ATTO 647N dye (8.14 µL, 0.01 µmol) was added and allowed to react 
for 2 h under cold sonication bath. The resulting ATTO@Glc-NCs were dialyzed against 
1.5 L MilliQ water three times. 
Cy5 tagged Glc-NCs (Cy5@Glc-NCs) 
 
A solution of Glc-NCs (5.0 mL, 1.4 µmol Au, 6.11 1015 nanoclusters) was diluted with 25 
mL MilliQ water and 500 µL PBS. To this solution, EDC (6.5 mg, 34 µmol) and sulfo-
NHS (7.4 mg, 34 µmol) were added dropwise and the reaction was allowed to stir for 5 
minutes under sonication in an ice bath. Subsequently, an aqueous solution of Cy5-NH2 
dye (6.6 µL, 0.01 µmol) was added and allowed to react for 2 h under cold sonication bath. 





Pyrimethamine functionalized Glc-NCs (Pyr@Glc-NCs) 
 
A solution of Glc-NCs (5.0 mL, 1.4 µmol Au, 6.11 1015 nanoclusters) was diluted with 25 
mL MilliQ water and 500 µL PBS. To this solution, EDC (6.5 mg, 34 µmol) and sulfo-
NHS (7.4 mg, 34 µmol) were added dropwise and the reaction was allowed to stir for 5 
minutes under sonication in an ice bath. Subsequently, a solution of pyrimethamine (0.03 
mg, 0.12 µmol) in DMSO was added and allowed to react for 2 h under cold sonication 
bath. The resulting Pyr@Glc-NCs were dialyzed against 1.5 L MilliQ water three times. 
3.4.3. Biology methods 
3.4.3.1. Plasmodium falciparum asexual culture 
The P. falciparum erythrocyte stages were cultured as previously reported.181 The asexual 
growth medium was composed of RPMI 1640 supplemented with 2 mM L-glutamine, 5 
mM HEPES buffer, 28 µg/mL hypoxanthine, 50 µg/mL gentamycin and 0.5% AlbuMAX™ 
II. Parasites were kept at 1% hematocrit in 150 cm2 cell culture flasks at 37 °C under 5% 
CO2.  
Thawing of P. falciparum glycerol-cryostocks 
Cryostocks of infected red blood cells (iRBCs) containing 3D7 P. falciparum strain were 
stored in 15% (v/v) glycerol and 1.5% (w/v) sorbitol in liquid nitrogen. The cryovial was 
thawed for 3 min in a 37 °C water bath and transferred into a 50 mL tube under sterile 
conditions. Subsequently, 0.1 times the volume of preheated thawing solution A (12% 
(w/v) NaCl) was added to the tube and the mixture was incubated for 5 min at room 
temperature. Then, 10 times the volume of preheated thawing solution B (1.6% (w/v) NaCl) 
was added dropwise while swirling the tube. The cell suspension was further centrifuged 
for 5 min at 300g and the pellet was washed once in 10 mL P. falciparum growth medium. 
Chapter 3. Targeting protozoan parasites using gold nanoclusters  
81 
 
The washed cells were added to a 150 cm2 cell culture flask containing 60 mL P. falciparum 
growth medium. Fresh red blood cells (RBC) of blood group O (ABO system) and Rhesus 
factor positive (Deutsches Rotes Kreuz e.V.) were added to a final hematocrit of 1%. The 
flask was maintained at 37 °C under 5% CO2. 
Cultivation of P. falciparum 
Life cycle stages as well as parasitemia were determined on a daily basis by light 
microscopy. For the microscope slide preparation, 1 mL of resuspended culture was 
centrifuged for 5 min at 300g and the supernatants were removed. The sample was smeared 
on the glass slides by taking 7.5 µL of the blood pellet. The slides were then allowed to dry 
and were further fixed with methanol. The parasites were then stained with UN 1230 
Giemsa staining solution, diluted to 6% (v/v) with staining buffer (7 mM phosphate, pH 
7.1) for visualization under the microscope.  
Sorbitol synchronization of P. falciparum 
Sorbitol synchronization allows for enrichment of ring staged parasites in culture through 
lysis of most iRBCs containing mid and late trophozoites as well as schizonts. The parasite 
cultures were centrifuged for 5 min at 400g. The resulting pellet was resuspended in 5 times 
the pellet volume of sterile and preheated 5% sorbitol solution (in MilliQ water). 
Afterwards, the cultures were incubated for 10 min at 37°C and shaken every 3 min in 
vortex mixer. Subsequently, the cultures were washed twice (400g, 10 min) with growth 
medium and transferred into a 150 cm2 cell culture flask containing 60 ml of medium. Fresh 
RBCs were added to a final hematocrit of 1%.  
Magnetic cell separation for schizont enrichment 
Since the haem moiety in the hemoglobin is diamagnetic, the iRBCs containing only mature 
parasites can be separated using magnetic-activated cell sorting (MACS) and LD columns. 
For this purpose, the LD columns were placed on a magnetic column holder and 
equilibrated using 2 mL of parasite growth medium. The cultures were centrifuged at 300g 
for 5 min to obtain the parasite pellets that were then loaded on the column followed by 4 
mL of growth medium. The flow through containing RBCs and ring stage iRBCs was 
collected and the column containing mature parasites was finally removed from the magnet 
and eluted with 2 mL of growth medium by applying pressure.  
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Saponin isolation of P. falciparum schizonts 
Saponin treatment leads to complete lysis of RBC and allows for the isolation of parasites. 
For this purpose, synchronized schizont stage cultures at very high parasitemia (>50%) 
were used. The cultures were therefore centrifuged (5 min, 400g) and resuspended in 
saponin solution (1 mL, 0.15%) and further incubated for 10 min in an ice bath, shaking 
the cultures every 3 min using a vortex mixer. The suspension was then centrifuged for 10 
min at 2000g keeping the temperature at 4 °C and the supernatant was discarded. The 
pellets were washed several times with ice cold PBS until the supernatant became clear. 
Percoll synchronization of P. falciparum 
Percoll synchronization allows for enrichment of mature staged parasites (schizonts) in the 
culture in a similar way as magnetic cell separation. The parasite cultures were centrifuged 
for 5 min at 300g. A solution of percoll 70% in PBS was pre-warmed and 1 mL of the pellet 
was gently deposited on top of this solution (using 15 mL falcon tubes). This resulting 
mixture was subsequently centrifuged at 800g for 10 min at 37 °C, putting the acceleration 
and brake to minimum. The resulting red upper layer is collected as it contains mature 
parasites and washed extensively with growth medium (300g, 5 min). The culture was then 
transferred into the culture flask or plate by adjusting (when required) the hematocrit to 
1%. 
3.4.3.2. Plasmodium falciparum sexual culture 
The P. falciparum gametocytes stages were obtained by a modification of a previously 
reported protocol.178 Parasites were kept at 5% hematocrit in 10-cm Petri dishes at 37 °C 
under 5% CO2, 5% O2, 90% N2 and 60% humidity.  
Different media were used: 
The asexual growth medium was composed of RPMI 1640 supplemented with 2 mM L-
glutamine, 5 mM HEPES buffer, 28 µg/mL hypoxanthine, 50 µg/mL gentamycin and 0.5% 
AlbuMAX™ II. 
The no-N-acetyl-glucosamine gametocyte medium (NNGM) was composed of RPMI 
1640 supplemented with 1 g of glucose, 28 µg/mL hypoxanthine, 25 mM of HEPES, and 
0.5% AlbuMAX™ II. This medium could be stored for no longer than 3 weeks at 4 °C. 
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The N-acetyl-glucosamine gametocyte medium (NGM) was composed of RPMI 1640 
supplemented with 1 g of glucose, 28 µg/mL hypoxanthine, 25 mM of HEPES, 5.8 g of  N-
acetyl-glucosamine, 0.5 mL of human serum and 0.5% AlbuMAX™ II. This medium could 
only be used when freshly prepared. 
For the gametocyte induction, a first asexual culturing and synchronization is required in 
order to initiate a log growth during the first ten days. This asexual culturing is followed 
by a gametocyte induction by mimicking host anemia through total RBC replacement, as 
well as by reducing the hematocrit from 5 to 1.25%. A further increase of % parasitemia 
also produces stressed parasites that induce gametocytogenesis. These parameters can be 
achieved by using either magnetic separation or percoll synchronization. Once the 
gametocytes are induced, they can be isolated depending on the early or late stage. 
Early staged gametocytes can be isolated by changing the asexual growth medium to 
NNGM, doing percoll synchronization in NGM instead of asexual growth medium. The 
gametocytes can then be used for confocal microscopy imaging. Parasites were kept at 5% 
hematocrit in 10-cm Petri dishes at 37 °C under 5% CO2, 5% O2, 90% N2 and 60% 
humidity. 
Late staged gametocytes can be isolated by changing the medium to NGM and doing 
percoll synchronization using NGM instead of the asexual growth medium. The 
gametocytes can then be used for confocal microscopy imaging. Parasites were further kept 
at 5% hematocrit in 10-cm Petri dishes at 37 °C under 5% CO2, 5% O2, 90% N2 and 60% 
humidity. 
3.4.3.3. ICP-AES 
Isolated mature parasites (by saponin) were thawed and washed with PBS (3000g, 5 min), 
and 500 µL of PBS was added to resuspend the pellet. Three different concentrations of 
Glc-NCs and Cit@AuNPs were used (5, 20, 50 µM). For each experiment, 20 µL of the 
resuspended parasites were incubated with 1 mL of each gold nanoparticle solution in PBS, 
for 15 min. The parasites were further washed three times with PBS (3000g, 5 min) and the 
pellet was treated with aqua regia and measured with ICP-AES. 
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3.4.3.4. Flow cytometry  
Flow cytometry is a very powerful technique that is able to analyze cells depending on 
morphology features by means of light scattering as well as give information about binding 
of fluorescent labelled probes. 
Parasitemia determination 
As RBCs do not contain DNA, the iRBCs can be distinguished by using a DNA staining 
dye (SYBRTM Green). For this purpose, 500 µL of a resuspended culture (containing 5 µL 
of RBCs) was centrifuged (300g, 5 min) and further washed with PBS. The pellet was then 
resuspended in 150 µL of PBS. Finally, 1 mL of PBS containing 4% PFA, 1 µL of the 
resuspended parasites and a solution of SYBRTM Green (dilution 1:10,000) were incubated 
for 20 min in absence of light. Non infected RBCs were used as control. The measurements 
were performed using a FITC channel.  
Binding studies with ATTO@Glc-NCs 
The parasitemia of a synchronized culture (rings, trophozoites or schizonts) was determined 
as previously described to adjust it to 1 and 10% parasitemia by adding fresh RBC. The 
experiment was performed using both % parasitemia. Then, 500 µL of a resuspended 
culture (containing 5 µL of RBCs) as well as 5 µL non-infected RBC were centrifuged 
(300g, 5 min) and further washed with PBS. Subsequently, 1 mL of a dilution of 
ATTO@Glc-NCs (20 µM concentration based on Au) in growth medium and PBS was 
added to each sample. To prepare this solution, 500 µL of ATTO@Glc-NCs (40 µM 
concentration based on Au) was diluted with 500 µL of growth medium and 50 µL of 10x 
PBS. The diluted ATTO@Glc-NCs were incubated with the parasites for 15 min under 
shaking and in the dark. The parasites were then thoroughly washed 3 times with PBS 
(300g, 5 min) and finally resuspended in 150 µL of PBS. Subsequently, 1 mL of PBS 
containing 4% PFA, 1 µL of the resuspended parasites and a solution of SYBRTM Green 
(dilution 1:10,000) were incubated for 20 min in absence of light. Non infected RBCs were 
used as control. The measurements were performed using a FITC channel to detect 
parasitemia and APC channel to detect ATTO@Glc-NCs. Non infected RBCs (treated and 
not treated with ATTO@Glc-NCs), as well as iRBC not treated with ATTO@Glc-NCs 
were used as control. Experiments were done in triplicates. 
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3.4.3.5. Confocal microscopy 
For confocal imaging binding studies of both asexual and sexual cultures, 500 µL of a 
resuspended culture (containing 5 µL of RBCs) as well as 5 µL non-infected RBC were 
centrifuged (300g, 5 min) and further washed with PBS. Subsequently, 1 mL of a dilution 
of ATTO@Glc-NCs (20 µM concentration based on Au) in growth medium and PBS was 
added to each sample. To prepare this solution, 500 µL of ATTO@Glc-NCs (40 µM 
concentration based on Au) was diluted with 500 µL of growth medium and 50 µL of 10x 
PBS. The diluted ATTO@Glc-NCs were incubated with the parasites for 15 min under 
shaking and protected from light. The parasites were then thoroughly washed 3 times with 
PBS (300g, 5 min) and finally fixed by incubation with 500 µL of PBS containing 4% PFA 
for 15 min. Parasites were then centrifuged one more time and resuspended in 30 µL of 
PBS. To this suspension, 30 µL of mounting solution containing DAPI was added and 
carefully mixed. Finally, 10 µL of this mixture was put on a glass slide, covered with a 
glass cover and fixed with nail polish. Non-infected RBCs (treated and not treated with 
ATTO@Glc-NCs), as well as iRBC not treated with ATTO@Glc-NCs were used as 
control. 
3.4.3.6. Hemolysis assay 
The parasitemia of a synchronized culture (rings, trophozoites or schizonts) was determined 
as previously described to adjust it to 1 and 10% parasitemia by adding fresh RBC. The 
experiment was performed using both % parasitemia. Then, 500 µL of a resuspended 
culture (containing 5 µL of RBCs) as well as 5 µL non-infected RBC were centrifuged 
(300g, 5 min) and further washed with PBS. Different concentrations of 300 µL of Glc-
NCs in PBS (50, 25, 12.5, 2.5, 0.25, 0.025 and 0.0025 µM concentration based on Au) were 
incubated with the cultures for 15 min. The different samples were then centrifuged (300g, 
5 min) and 50 µL of the supernatants were put in a Greiner 96 V Bottom Transparent 
Polystyrol in triplicates. The absorbance at 540 nm was read using a plate reader. 
Supernatants of RBC and iRBC treated with PBS (negative control) and saponin (positive 

















This chapter has been modified in part from the following article: 
Reshaping silica particles: Mesoporous nanodiscs for bimodal delivery and improved 
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5.	 	 Synthesis	 of	 multivalent	 glycosylated	
nanoparticles	for	imaging	
5.1. Introduction 
Glycosylated nanoparticles are used to mimic multivalent systems in nature and give 
information about biological processes that occur through carbohydrate-carbohydrate 
(CCIs) and carbohydrate-protein interactions (CPIs). There are three main conjugation 
strategies used to glycosylate nanoparticles: covalent bond formation through amides or 
ester bonds, direct conjugation to metal surfaces (i.e. thiol chemistry), and [3+2] 
cycloaddition (click) chemistry (Figure 5.1).216 
 
Figure 5.1. Conjugation strategies for glycosylation of nanoparticles through a) coupling reaction to form amides or 
esters, b) thiol conjugation to metals, and c) click chemistry. 
Coupling reactions to form amides and esters are common methods to functionalize 
surfaces, as there are orthogonal to  other strategies, such as click chemistry.216  
Direct conjugation of thiols to metal nanoparticles has been exploited for plasmonic assays 
such as surface plasmon resonance (SPR) or surface-enhanced Raman spectroscopy 
(SERS), as it provides a stable bond that can be further utilized for biomolecular 
interactions studies. The addition of mixed thiol ligands allows for multiple 




Click reactions are an attractive surface functionalization strategy due to the orthogonality 
to other conjugation strategies. Nevertheless, the use of copper as a catalyst is often 
problematic to purify as it can be trapped at the surface or even bind triazoles. Moreover, 
terminal alkynes are also able to bind metal surfaces through non-specific interactions.217   
In this chapter, glycosylation of nanoparticles was performed to promote the blood brain 
barrier crossing and to monitor the CPIs between cyanobacteria and microalgae. Glucose 
was conjugated through a coupling reaction to the surface of ultrasmall silicon 
nanoparticles (SiNPs) in order to enable the blood brain barrier (BBB) crossing. Ultrasmall 
SiNPs have already been used as multivalent glycosylated scaffolds as they can be 
exploited for multivalent conjugation, they exhibit fluorescent properties for imaging and 
they provide easy conjugation and low cytotoxicity.54-55 The double conjugation of glucose 
and a chelator that hosts a radiotracer was carried out for further in vivo studies in mice. 
Gold nanoparticles (AuNPs) functionalized with different carbohydrates were also 
synthesized in order to study CPIs between microalgae and cyanobacteria as they form cell-
cell aggregates. Green algae express mannosides on the surface and cyanobacteria contain 
external lectins.218 To further explore the CPIs between the mannosides and the 
cyanobacteria, a collection of different carbohydrates was synthesized and conjugated to 
gold nanoparticles through thiol conjugation. The glycosylated nanoparticles will be further 
tested using confocal microscopy to analyze the structure that provides the highest affinity 
to the lectin. 
5.2. Results 
5.2.1. Glucose-functionalized silicon nanoparticles for brain 
imaging 
Fluorescent ultrasmall silicon nanoparticles (SiNPs)g that have a size of 4 nm, can be used 
for brain targeting and imaging. SiNPs were functionalized with glucose, to target the brain, 
and the chelator 1,4,7-triazacyclononane-1,4,7-trisacetic acid (NOTA), for radiolabeling. 
                                               
g SiNPs were synthesized by Mr. John Ddungu and Ms. Alessandra Tassoni from the group of Prof. Luisa 
De Cola, Université de Strasbourg, CNRS, ISIS, Strasbourg, France. 
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As SiNPs were stabilized with amines, compound 4 was equipped with a carboxylic acid 
(5),h using succinic anhydride in the presence of N,N-diisopropylethylamine (DIPEA) 
(Scheme 5.1). 
 
Scheme 5.1. Synthesis of carboxylic acid functionalized glucoside 5. 
SiNPs functionalized with a NOTA chelator (SiNPs-NOTA)i were conjugated to the 
carboxylic acid modified glucoside 5 through an amide coupling reaction using EDC/NHS 
activation, in PBS buffer to yield Glc@SiNPs-NOTA (Scheme 5.2). The product was 
further purified, firstly by dialysis against MilliQ water for two days, and afterwards by 
size exclusion column to remove unreacted glucosides. 
 
Scheme 5.2. Conjugation of SiNPs-NOTA to the glucoside 5 using EDC/NHS activation to yield Glc@SiNPs-
NOTA.  
Dynamic light scattering (DLS) showed a slight increase in the size of Glc@SiNPs-NOTA 
(Figure 5.2 b), when compared to SiNPs-NOTA due to the sugar functionalization (Figure 
                                               
h Compound 4 was synthesized by Dr. Chian-Hui Lai 
 
i SiNPs-NOTA were functionalized by Ms. Garima Singh, from the group of Dr. Holger Stephan, Institute 





5.2 a). The zeta (ζ) potential decreased slightly for Glc@SiNPs-NOTA compared to 
SiNPs-NOTA due to glucose functionalization (Figure 5.2). 
 
Figure 5.2. Dynamic light scattering of a) SiNPs-NOTA and b) Glc@SiNPs-NOTA, and c) Zeta potential of SiNPs-
NOTA and Glc@SiNPs-NOTA. 
Infrared spectroscopy (IR) confirmed the functionalization of Glc@SiNPs-NOTA as the 
spectrum showed the appearance of characteristic bands (Figure 5.3). SiNPs-NOTA had 
still available amine groups as stabilizer, which were detected by the N-H bending at 1600 
cm-1. In Glc@SiNPs-NOTA the band at 1640-1690 cm-1 corresponds to the C-O stretch 
and the band at 1550 cm-1 is a result of the N-H bending by the amide formation. Moreover, 
the hydroxyl groups of the glucose can be seen through the band at 1050-1150 cm-1 (C-O 
stretch).  




Figure 5.3. IR spectra of SiNPs-NOTA (above) and Glc@SiNPs-NOTA (below). 
The loading of glucose on Glc@SiNPs-NOTA was quantified by using the anthrone 
method.112 Anthrone reacts with hexoses in the presence of sulfuric acid, to form a colored 
compound that can be detected by UV spectroscopy (Scheme 5.3). The reaction is 
concentration dependent and can be monitored by measuring the absorbance at 620 nm. 
 
Scheme 5.3. Colorimetric reaction between anthrone and hexoses in acidic conditions. 
Stock solutions of glucose in water (0.25 - 0 mg/mL) were prepared and allowed to react 
with anthrone under acidic conditions. The absorbance was then measured at 620 nm to 
obtain a calibration curve (Figure 5.4). Interpolation of the absorbance values of 
Glc@SiNPs-NOTA, after subtracting the value of SiNPs-NOTA, gave the loading of 





Figure 5.4. Calibration curve for glucose quantification in Glc@SiNPs-NOTA. 
The fully characterized Glc@SiNPs-NOTA were sent to the group of Dr. Holger Stephan 
at Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden - 
Rossendorf (HZDR), Germany. Radiolabeling and in vivo studies in mice are currently 
under investigation to test whether the nanoparticles are able to cross the blood brain 
barrier.  
5.2.2 Glycosylated gold nanoparticles for CPIs studies 
Gold nanoparticles (AuNPs) with a plasmon band can be used as a multivalent platform for 
interactions studies using confocal microscopy.219 Citrate stabilized nanoparticles (Cit-
AuNPs) were synthesizedj as they show a plasmon band at ~520 nm that can be imaged 
with confocal microscopy. A collection of different carbohydratesk (Figure 5.5) were 
synthesized and conjugated to Cit-AuNPs in order to monitor the structure that has more 
affinity to the lectin exposed on cyanobacteria. Mannoside 6 and 8 were selected to 
understand whether there is a difference in monosaccharide vs disaccharide binding. The 
galactoside 7 was chosen as a control as it should not bind the lectin. 
                                               
j Synthesis of Cit-AuNPs is shown in Chapter 3. 
 
k Collection of carbohydrates 6, 7 and 8 were synthesized by Dr Martina Delbianco.  




Figure 5.5. Selection of thiolated carbohydrates conjugated to Cit-AuNPs for CPIs studies between green algae and 
cyanobateria. 
Conjugation of carbohydrates 6, 7 and 8 to Cit-AuNPs was carried out by adding an excess 
of the compounds at room temperature and was allowed to react for 24 h to ensure complete 
functionalization (Scheme 5.4). The products (Man@AuNPs, DiMan@AuNPs and 
Gal@AuNPs) were purified by dialysis against MilliQ water.  
 
Scheme 5.4. Conjugation of compoiunds 6, 7 and 8 to Cit-AuNPs to yield Man@AuNPs, Gal@AuNPs and 
DiMan@AuNPs, respectively. 
After conjugation of the different carbohydrates, plasmon resonance was measured with 
UV and the size and morphology was assessed with transmision electron microscopy 




nanoparticles (Figure 5.6). The plasmon band was detected in the three samples at 527 nm 
and the particle size was found to be ~20 nm. 
 
Figure 5.6. UV spectra (above) and transmission electron microscopy (below) of a) Man@AuNPs, b) Gal@AuNPs, and 
c) DiMan@AuNPs. Scale bar = 50 nm 
ζ potential was measured in order to analyze the surface charge difference after nanoparticle 
functionalization. The ζ potential values became significantly more negative after 
carbohydrate conjugation, as Cit-AuNPs showed a ζ potential of -20 mV and after 
carbohydrate conjugation the surface ζ potential decreased to values between -30 and -40 
mV. This suggests an increase in the stability of the carbohydrate functionalized 
nanoparticles (Figure 5.7).  
 
Figure 5.7. Zeta potential of Man@AuNPs, Gal@AuNPs, DiMan@AuNPs and Cit-AuNPs. 
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The difference in the ζ potential between the three carbohydrate-conjugated samples could 
be explained due to difference in the loading of the glycoconjugates. Carbohydrate loading 
was calculated by using the previously described anthrone method (Section 5.2). For this, 
two calibration curves were obtained: one using a monosaccharide as standard and the other 




Figure 5.8. Calibration curve for the sugar quantification of Man@AuNPs, Gal@AuNPs, using monosaccharide 




Interpolation in the calibration curves gave the loading of the different carbohydrates that 
was expressed by µg carbohydrate per µmol of atomic gold (Table 5.1). These results are 
in agreement with Zeta potential, as less loading shows a lower zeta potential value.  
Table 5.1. Carbohydrate loading on Man@AuNPs, Gal@AuNPs and DiMan@AuNPs calculated from the calibration 
curves. 
 Man@AuNPs Gal@AuNPs DiMan@AuNPs 
Loading (µg/µmol) 61.5 36.9 49.3 
 
The three samples (Man@AuNPs, Gal@AuNPs and DiMan@AuNPs) were sent to the 
group of Dr. Thomas R. Neu, Department of River Ecology at Helmholtz Centre for 
Environmental Research Magdeburg, Germany. CPIs studies with confocal microscopy are 
currently under investigation.  
5.3. Conclusion and outlook 
Glycosylated nanoparticles were used to create multivalent platforms to gain a better 
insight into complex biological processes that involve carbohydrates. In particular, 
ultrasmall silicon nanoparticles have the proper size to potentially cross the BBB. For this 
purpose, silicon nanoparticles were functionalized with glucose to target the brain, and a 
chelator to host a radiotracer for imaging. The fully characterized material is currently being 
studied in a mouse model. Conjugation of pharmaceuticals to glycosylated ultrasmall 
nanoparticles can open opportunities to treat severe brain diseases such as brain tumors, 
cerebral malaria, Parkinson's disease or Alzheimer's disease.  
Plasmonic nanoparticles were conjugated to different carbohydrates for binding studies 
between green microalgae and cyanobacteria using CLSM. The adhesion process is known 
to occur though CPIs, but the exact structure of the carbohydrate epitope involved in the 
binding is unknown. Synthesis of a collection of carbohydrates can give information of the 
structure that gives the highest affinity to the lectin.  
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5.4. Experimental section 
5.4.1. General methods 
All reagents were commercially purchased and used without further purification. 
Anhydrous solvents were obtained from a Dry Solvent System (jcmeyer-solvent system). 
Air sensitive reactions were carried out using oven-dried glassware and under an 
atmosphere of argon or nitrogen. 
Thin-layer chromatography (TLC) was carried out on ALUGRAM® Xtra SIL plates pre-
coated with silica gel of 0.20 mm thickness (Macherey-Nagel). TLC spots were visualized 
either under UV irradiation (254/366 nm) or by dipping the TLC in sugar stain (0.1% (v/v) 
3-methoxyphenol, 2.5% (v/v) sulfuric acid in EtOH).  
Lyophilized water containing samples were performed using an Alpha 2-4 LD Lyophilizer 
(Christ, Osterode am Harz, Germany) 
1H and 13C and two dimensional NMR data were obtained on Bruker ECX 400 MHz, amd 
Varian 400 MHz NMR spectrometers. 
FTIR spectra were recorded on a Spectrum 100 FT-IR spectrometer (Perkin Elmer). The 
samples were spotted as a solid on the detector before measurements. 
Transmission electron microscopy (TEM) measurements were performed on a Zeiss EM 
912 Omega. The samples were prepared by immersion of grids into a small volume of the 
sample and subsequent solvent evaporation in a dust protected atmosphere. 
UV/Vis spectra were recorded on Shimadzu UV-3600 spectrophotometer double-beam 
UV–VIS–NIR spectrometer and baseline corrected.  
Dynamic light scattering (DLS) measurements were carried out at a scattering angle of 
173° with a Malvern Zeta Nanosizer working at 4-mW He–Ne laser (633 nm). The Glc-
NCs were measured in MilliQ water. 
ζ potential was measured using a Malvern Zetasizer instrument in order to obtain the 
electrophoretic mobility of nanoparticles at different times of dialysis against MilliQ water. 




mobilities to the zeta potentials. Three replicates of each sample were measured six times 
at 25 °C in MilliQ water. 
5.4.2. Synthetic chemistry methods 
4-oxo-4-((5-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-
pyran-2-yl)oxy)pentyl)amino)butanoic acid (5) 
 
Compound 4 (15 mg, 57 µmol) was dissolved in 2 mL DMF and DIPEA (10 µL, 57 µmol) 
was added at 0 °C. Then, succinic anhydride (5.7 mg, 57 µmol) was added and the mixture 
was allowed to stir for 4 h at 0 °C. The reaction mixture was diluted with water and 
concentrated in vacuum. The crude compound was purified using a Chromafix® C18 
column (water/MeOH 1:4) to obtain the desired compound 5 (17.5 mg, 85% yield). 
1H NMR (400 MHz, D2O) δ 4.32 (d, J = 8.0 Hz, 1H), 3.82 – 3.78 (m, 1H), 3.77 (q, J = 2.2, 
1.5 Hz, 1H), 3.62 – 3.50 (m, 2H), 3.38 – 3.28 (m, 2H), 3.24 (dd, J = 9.8, 8.9 Hz, 1H), 3.12 
(dd, J = 9.3, 8.0 Hz, 1H), 3.06 (t, J = 6.8 Hz, 2H), 2.52 – 2.47 (m, 2H), 2.38 (t, J = 6.6 Hz, 
2H), 1.51 (dq, J = 14.4, 6.8 Hz, 2H), 1.40 (p, J = 7.0 Hz, 2H), 1.29 – 1.20 (m, 2H). 13C 
NMR (101 MHz, D2O) δ 177.58, 174.70, 102.06, 75.80, 75.70, 73.04, 70.28, 69.56, 60.65, 
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Glucose functionalized silicon nanoparticles containing NOTA (Glc@SiNPs-NOTA) 
 
Compound 5 (9 mg, 23 µmol) was dissolved with 20 mL MilliQ water. To this solution, 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, 20 mg, 129 µmol) and N-
hydroxysulfosuccinimide  (sulfo-NHS, 25 mg, 129 µmol) in PBS were added dropwise and 
allowed to stir for 5 min. Subsequently, an aqueous solution of SiNPs-NOTA (5 mg, 2 mL) 
was added and allowed to react for 24 h. The resulting Glc@SiNPs-NOTA were dialyzed 
against 1.5 L MilliQ water three times and purified with size exclusion column PD10 
(Sephadex) using MilliQ water.                                                                                                                                                                                                                                                              
Mannose functionalized gold nanoparticles (Man@AuNPs) 
 
An aqueous solution of Cit-AuNPs (135 µmol, 2 mL) was mixed with compound 6 (0.2 
mg, 0.3 µmol) in water and allowed to stir for 24 h at room temperature. The Man@AuNPs 






Galactose functionalized gold nanoparticles (Gal@AuNPs) 
 
An aqueous solution of Cit-AuNPs (135 µmol, 2 mL) was mixed with compound 7 (0.2 
mg, 0.3 µmol) in water and allowed to stir for 24 h at room temperature. The Gal@AuNPs 
were then dialyzed against 1.5 L MilliQ water three times. 
Di-mannose functionalized gold nanoparticles (DiMan@AuNPs) 
 
An aqueous solution of Cit-AuNPs (135 µmol, 2 mL) was mixed with compound 8 (0.3 
mg, 0.3 µmol) in water and allowed to stir for 24 h at room temperature. The 
DiMan@AuNPs were then dialyzed against 1.5 L MilliQ water three times. 
Carbohydrate quantification on nanoparticles 
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A freshly prepared solution of anthrone (0.5%, w/w) in sulfuric acid was added slowly to 
0.5 mL the stock solutions or the nanoparticle samples. The resulting solution was gently 
mixed and heated to 80 ºC for 10 min. The absorption was recorded at 620 nm to make the 




































In this dissertation, a different method to obtain ultrasmall gold nanoparticles (2 nm) using 
a thio-glycoside as a reducing and stabilizing agent was developed. These nanoparticles 
were tested in biological media and showed high biocompatibility both in vitro and in vivo. 
Due to the surface chemistry of the protozoan parasites Plasmodium falciparum and 
Toxoplasma gondii, gold nanoparticles were used for binding studies, as the cysteine-rich 
domains present on the surface proteins of these protozoan parasites were targeted, through 
the well-known thiol-gold linkage. The high binding efficiency of gold nanoparticles to all 
of the blood stages of P. falciparum, as well as extracellular and intracellular T. gondii, 
shows promising applications for drug delivery discoveries. Drug conjugation was carried 
out for in vitro and in vivo inhibition studies by comparing the therapeutic activity of drug-
loaded nanoparticles to same concentration of free drug. Targeted delivery can reduce the 
drug dosage needed, which reduces drug resistance that is a major problem in the treatment 
of parasite-related diseases. In order to prove that the binding of gold nanoparticles to the 
protozoan parasites occurs through cysteine-rich domains, cysteine blocking experiments 
can be further carried out to protect the thiol group and avoid conjugation to gold. To 
enhance the targeting efficiency for further therapeutic studies, especially in intracellular 
T. gondii, single domain antibodies can be conjugated to the gold nanoparticles. These 
types of antibodies exhibit better stability, functionality, epitope binding and therapeutic 
applications compared to conventional antibodies. The conjugation of single domain 
antibodies, for targeting and for a certain therapeutic activity, to nanoparticles can provide 
a multimodal nanoparticle for theranostics of parasitic infectious diseases. The application 
of these multimodal nanoparticles can be further extended to other targeting diseases such 
as cancer. 
Mesoporous silica nanoparticles have been used in cancer drug delivery due to the 
mesoporous framework that can capture and release cargo. Flat discs were synthesized to 
increase the surface contact with the cells. This novel shape showed improved cellular 




nanodiscs were doped with different percentages of cleavable moieties within the 
framework in order to hold the cargo until the particles are internalized by the cells. The 
doped particles showed a more controlled release of the cargo compared to non-doped 
particles, which is an important feature in order to avoid nonspecific release of drugs. The 
particles underwent classical endocytosis through endosomes and the silica debris 
underwent exocytosis once the particles were degraded. A study on the breakability of the 
particles showed that the higher the percentage of cleavable bonds, the higher the 
hydrophobicity of the particles. Nevertheless, without the introduction of cleavable bonds 
that would selectively break the particles only once they are internalized, cargo release 
would occur dependent on time and not location. Therefore, introduction of carbohydrates 
as cleavable moieties would solve the problem of hydrophobicity and also provide 
responsiveness under certain conditions (such as a specific pH, or the presence of enzymes).  
For targeted drug delivery, it is important to introduce available targeting biomolecules that 
could bind overexpressed receptors on targeted cells. Functionalization of breakable 
nanodiscs with carbohydrates could provide a fully engineered responsive nanocarrier that 
would be taken up only by the targeted cells and ensure the cargo release only upon particle 
internalization. This allows for using a lower dosage of drug, as the therapeutic activity is 
localized, which results in decreased side effects. 
The use of glycosylated nanoparticles for targeting and binding studies was further 
assessed. Ultrasmall fluorescent silicon nanoparticles were functionalized with a glucoside 
to facilitate the blood brain barrier crossing. The glucose-functionalized nanoparticles 
containing a radiotracer are being tested in vivo. The possibility to enable the blood brain 
barrier crossing will open up opportunities for targeted delivery of common brain diseases 
such as brain tumors or Alzheimer’s disease, and also severe brain infections such as 
cerebral malaria or toxoplasmosis. 
Carbohydrate-protein interactions occur through a certain carbohydrate epitope. Knowing 
the smallest epitope that is able to effect an interaction with proteins in high affinity is 
important to understand these processes and to build up nanotechnology tools. For this 
purpose, different glycosylated plasmonic nanoparticles were synthesized in order to 
analyze carbohydrate-protein interactions between green microalgae and cyanobacteria. 
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Further studies on this topic will give information on biological processes that are still 
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